{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff31507\deff0\stshfdbch31505\stshfloch31506\stshfhich31506\stshfbi31507\deflang16393\deflangfe16393\themelang16393\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f34\fbidi \froman\fcharset0\fprq2{\*\panose 02040503050406030204}Cambria Math;}
{\f37\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}{\f43\fbidi \froman\fcharset0\fprq0{\*\panose 00000000000000000000}TimesNewRomanPS-BoldMT{\*\falt Times New Roman};}
{\f44\fbidi \froman\fcharset0\fprq0{\*\panose 00000000000000000000}TimesNewRomanPSMT{\*\falt Times New Roman};}{\f45\fbidi \froman\fcharset0\fprq0{\*\panose 00000000000000000000}TimesNewRomanPS-ItalicMT{\*\falt Times New Roman};}
{\f46\fbidi \froman\fcharset0\fprq0{\*\panose 00000000000000000000}TimesNewRomanPS-BoldItalicMT{\*\falt Times New Roman};}{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}
{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}
{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f432\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\f433\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}
{\f435\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\f436\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\f437\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\f438\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}
{\f439\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\f440\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\f772\fbidi \froman\fcharset238\fprq2 Cambria Math CE;}{\f773\fbidi \froman\fcharset204\fprq2 Cambria Math Cyr;}
{\f775\fbidi \froman\fcharset161\fprq2 Cambria Math Greek;}{\f776\fbidi \froman\fcharset162\fprq2 Cambria Math Tur;}{\f779\fbidi \froman\fcharset186\fprq2 Cambria Math Baltic;}{\f780\fbidi \froman\fcharset163\fprq2 Cambria Math (Vietnamese);}
{\f802\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}{\f803\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}{\f805\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\f806\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}
{\f807\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew);}{\f808\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic);}{\f809\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}{\f810\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese);}
{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}
{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}
{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}
{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}
{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}
{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}
{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}
{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}
{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}
{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}
{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}
{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}
{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}
{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}
{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}
{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}
{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew);}{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic);}{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}
{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese);}{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}
{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}}
{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;
\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;\red0\green0\blue0;\red51\green102\blue255;}{\*\defchp \fs22\loch\af31506\hich\af31506\dbch\af31505 }{\*\defpap 
\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 
\af31507\afs22\alang1025 \ltrch\fcs0 \fs22\lang16393\langfe16393\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp16393\langfenp16393 \snext0 \sqformat \spriority0 Normal;}{\*\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}
{\*\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\trcbpat1\trcfpat1\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs22\alang1025 \ltrch\fcs0 \fs22\lang16393\langfe16393\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp16393\langfenp16393 
\snext11 \ssemihidden \sunhideused Normal Table;}}{\*\rsidtbl \rsid6642081\rsid7741077}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\author Dr. Collins}
{\operator Admin}{\creatim\yr2019\mo3\dy13\hr20\min28}{\revtim\yr2019\mo3\dy13\hr20\min28}{\version2}{\edmins1}{\nofpages22}{\nofwords10598}{\nofchars60409}{\nofcharsws70866}{\vern99}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wor
dml}}\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont0\relyonvml0\donotembedlingdata1\grfdocevents0\validatexml0\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors0\horzdoc\dghspace120\dgvspace120\dghorigin1701
\dgvorigin1984\dghshow0\dgvshow3\jcompress\viewkind1\viewscale100\rsidroot6642081 \fet0{\*\wgrffmtfilter 2450}\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2
\pnucltr\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6
\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}\pard\plain \ltrpar\qc \li0\ri0\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs22\alang1025 \ltrch\fcs0 \fs22\lang16393\langfe16393\loch\af31506\hich\af31506\dbch\af31505\cgrid\langnp16393\langfenp16393 {
\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\insrsid7741077 \hich\af43\dbch\af31505\loch\f43 \hich\f43 The Marketing of OxyContin\'ae\loch\f43 : A Cautionary Tale
\par }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\par \hich\af44\dbch\af31505\loch\f44 Submitted by:
\par \hich\af44\dbch\af31505\loch\f44 David Egilman, MD, MPH
\par \hich\af44\dbch\af31505\loch\f44 Never Again Consulting
\par \hich\af44\dbch\af31505\loch\f44 Clinical Associate Professor, Dept. of Community Health at Brown University
\par \hich\af44\dbch\af31505\loch\f44 8 North Main Street Suite 404
\par \hich\af44\dbch\af31505\loch\f44 Attleboro, MA 02703-2282
\par \hich\af44\dbch\af31505\loch\f44 degilman@egilman.com
\par \hich\af44\dbch\af31505\loch\f44 Office: (508) 226-5091
\par \hich\af44\dbch\af31505\loch\f44 Fax: (425) 699-7033
\par \hich\af44\dbch\af31505\loch\f44  
\par \hich\af44\dbch\af31505\loch\f44 Gregory B. Collins, M.D., D.F.A.P.A.
\par \hich\af44\dbch\af31505\loch\f44 Staff Psychiatrist and\hich\af44\dbch\af31505\loch\f44  Former Medical Director
\par \hich\af44\dbch\af31505\loch\f44 Department of Behavioral Health
\par \hich\af44\dbch\af31505\loch\f44 Moore Regional Hospital
\par \hich\af44\dbch\af31505\loch\f44 Pinehurst, NC 28374
\par \hich\af44\dbch\af31505\loch\f44 drgbcollins@yahoo.com
\par \hich\af44\dbch\af31505\loch\f44 Phone: (216) 346-0671
\par \hich\af44\dbch\af31505\loch\f44 Fax: (910) 420-2862
\par \hich\af44\dbch\af31505\loch\f44  
\par \hich\af44\dbch\af31505\loch\f44 Julie Falender, JD
\par \hich\af44\dbch\af31505\loch\f44 Phone: (401) 378-7417
\par 
\par \hich\af44\dbch\af31505\loch\f44 Naomie Shembo
\par \hich\af44\dbch\af31505\loch\f44 Brown University and Never Again \hich\af44\dbch\af31505\loch\f44 Consulting
\par \hich\af44\dbch\af31505\loch\f44 Naomie_Shembo@Brown.edu
\par 
\par \hich\af44\dbch\af31505\loch\f44 Ciara Keegan
\par \hich\af44\dbch\af31505\loch\f44 Brown University and Never Again Consulting
\par \hich\af44\dbch\af31505\loch\f44 Ciara_Keegan@Brown.edu
\par 
\par \hich\af44\dbch\af31505\loch\f44 Sunil Tohan
\par \hich\af44\dbch\af31505\loch\f44 Brown University and Never Again Consulting
\par \hich\af44\dbch\af31505\loch\f44 Sunil_Tohan@Brown.edu
\par 
\par }\pard \ltrpar\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\insrsid7741077 
\par \hich\af43\dbch\af31505\loch\f43 Author disclaimer:
\par }\pard \ltrpar\qj \li0\ri0\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 DE and GC have consulted on OxyContin\'ae\loch\f44  litigation.
\par }\pard \ltrpar\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 Word Count: 8053 words
\par 
\par \hich\af44\dbch\af31505\loch\f44 Abstract:
\par \hich\af44\dbch\af31505\loch\f44  
\par \hich\af44\dbch\af31505\loch\f44 This paper provides a review of the Purdue Pharma, L.P\hich\f44 \rquote \loch\f44 \hich\f44 s development and marketing of the long-acting oral narcotic OxyContin\'ae\loch\f44 .  Within five years of the drug\hich\f44 
\rquote \loch\f44 s launch, \hich\af44\dbch\af31505\loch\f44 \hich\f44 OxyContin\'ae\loch\f44 \hich\f44 
 became the number-one prescribed Schedule II narcotic in the United States.  The commercial success was in part the result of a marketing campaign that promoted questionably \'93\loch\f44 \hich\f44 distinctive\'94\loch\f44 
 benefits of the product, and minimized the very real dan\hich\af44\dbch\af31505\loch\f44 g\hich\af44\dbch\af31505\loch\f44 \hich\f44 ers of OxyContin\'ae\loch\f44 \hich\f44 
, which include abuse, diversion, addiction, overdose and death.  The marketing of OxyContin\'ae\loch\f44  was heavily based on scientifically invalid or unproven claims of safety and efficacy, on approved indications which were inappropriate, on off-
\hich\af44\dbch\af31505\loch\f44 l\hich\af44\dbch\af31505\loch\f44 
abel marketing and on inadequate warnings.  The FDA belatedly asked Purdue to voluntarily change some of the marketing language, but ironically Purdue exploited these changes to further marketing objectives and mislead health care practitioners about addi
\hich\af44\dbch\af31505\loch\f44 c\hich\af44\dbch\af31505\loch\f44 \hich\f44 tion risks.  The OxyContin\'ae\loch\f44 
 story exemplifies the many ways pharmaceutical manufacturers can undermine and compromise the regulatory process to increase profits at the expense of patient health. Purdue externalized the costs of the harm to patients, their
\hich\af44\dbch\af31505\loch\f44  \hich\af44\dbch\af31505\loch\f44 
families and society. This case brings to light important questions of industry and governmental/regulatory accountability and responsibility for the production, marketing and sale of pharmaceutical products that substantially increase risk while driving 
\hich\af44\dbch\af31505\loch\f44 g\hich\af44\dbch\af31505\loch\f44 reatly enhanced profits.
\par \page 
\par }\pard \ltrpar\ql \li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\ul\insrsid7741077 \hich\af43\dbch\af31505\loch\f43 Introduction
\par }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
The development and marketing of new drugs inevitably involves striking a balance between efficacy and safety for patients, and profit for the pharmaceutical company. Unfortunately, such a salutary balance is not al\hich\af44\dbch\af31505\loch\f44 
ways achieved, as overly aggressive, even misleading, marketing by a drug company can put the health and safety of patients at undue risk. We review Purdue Pharma and its partner Abbott Laboratories\hich\f44 \rquote \loch\f44 \hich\f44 
 marketing of the long-acting oral narcotic OxyContin\'ae\loch\f44 . \hich\af44\dbch\af31505\loch\f44 T\hich\af44\dbch\af31505\loch\f44 \hich\f44 he OxyContin\'ae\loch\f44 
 history provides a cautionary tale of aggressive, profit-driven marketing of a dangerous drug with inadequate preclinical testing for safety; high risks of addiction, overdose, and death; grossly insufficient, misleading warnings on the prod
\hich\af44\dbch\af31505\loch\f44 u\hich\af44\dbch\af31505\loch\f44 
ct label; unbalanced advertising; and regulatory compromise. The Food and Drug Administration (FDA), although charged with protecting the public by monitoring the preclinical trials, marketing, advertising and promotion of new drugs, suffered from industr
\hich\af44\dbch\af31505\loch\f44 y\hich\af44\dbch\af31505\loch\f44  regulatory capture, and failed to protect the public from the deceptive marketing of a dangerous pharmaceutical product.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 1-8}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\par \hich\af44\dbch\af31505\loch\f44 \hich\f44 In the early 1990s, Purdue Pharma was faced with the imminent expiration of its patent on MS Contin\'ae\loch\f44 \hich\f44 
, a long-acting, (q12 hour) morphine-containing pain medication.  Threatened with the specter of competition from generics, Purdue developed OxyContin\'ae\loch\f44 , a \hich\af44\dbch\af31505\loch\f44 s\hich\af44\dbch\af31505\loch\f44 \hich\f44 
low-release version of oxycodone, as a new q12 hour pain reliever. The FDA approved OxyContin\'ae\loch\f44 \hich\f44  in 1995. Purdue launched sales in 1996 marketing OxyContin\'ae\loch\f44 \hich\f44 
 as the longest-acting narcotic pain reliever available.  Purdue promoted OxyContin\'ae\loch\f44  as a superior al\hich\af44\dbch\af31505\loch\f44 t\hich\af44\dbch\af31505\loch\f44 
ernative to other pain medications such as Percocet and Percodan, which afford shorter periods of pain relief (4 to 6 hours.).}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 1}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  Purdue\hich\f44 \rquote \loch\f44 s marketing was incredibly successful, shown through dramatic increases in sales.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 2,3}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  By 2000, US health professionals had\hich\af44\dbch\af31505\loch\f44 \hich\f44 
 written approximately 5.8 million OxyContin\'ae\loch\f44 \hich\f44  prescriptions, and OxyContin\'ae\loch\f44  had become the number-one prescribed Schedule II narcotic in the United States.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 1}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44   
\par \hich\af44\dbch\af31505\loch\f44 Unfortunately, this commercial success was at least in part the result of a Purdue marketing camp\hich\af44\dbch\af31505\loch\f44 \hich\f44 
aign that included off-label sales, that promoted questionably unique benefits of the product, and that minimized the very real dangers of OxyContin\'ae\loch\f44 , including abuse, diversion, addiction, overdose and death.}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 3}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  Since the OxyContin\'ae\rquote \loch\f44 s introduction in 1996, 
\hich\af44\dbch\af31505\loch\f44 opioid related deaths have increased dramatically. In the past two decades, over 200,000 people have died in the US due to prescription opioid overdoses alone.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 4
\par }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 A confidential justice department (DOJ) report from 2006 shows that Purdue Pharma was aware of \hich\af44\dbch\af31505\loch\f44 \hich\f44 
the widespread abuse of OxyContin\'ae\loch\f44  and proceeded to conceal this information until it was leaked to Barry Meier in 2017 who published some parts of the investigatory record.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 5}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  At the conclusion of a four-year long investigation, the Department of Justice re\hich\af44\dbch\af31505\loch\f44 
commended that three Purdue Pharma executives be charged with felonies.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 4 }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 This investigation provided an opportunity to expose the illuminating evidence against Purdue that prosecutors had collected. Unfortunately, the George W. Bush administration at the t\hich\af44\dbch\af31505\loch\f44 
ime did not support this indictment, and the DOJ allowed the three Purdue executives to plead guilty to misdemeanors.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 4 }{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 More importantly, the DOJ sealed the investigatory record and Purdue\hich\f44 \rquote \loch\f44 s misleading branding and marketing tactics never became public. Wid
\hich\af44\dbch\af31505\loch\f44 \hich\f44 espread awareness of the dangerous potential of OxyContin\'ae\loch\f44 \hich\f44  was not achieved until it was too late. Instead, aggressive marketing and resultant prescribing of Oxycontin\'ae\loch\f44 
 increased. From 2002-2009 the number of extended release opioid prescriptions increase\hich\af44\dbch\af31505\loch\f44 d\hich\af44\dbch\af31505\loch\f44  146%, from 9.3 to 22.9 million.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 6}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\par \hich\af44\dbch\af31505\loch\f44 As the opioid epidemic has worsened and gained more publicity, awareness of the dangers of prescription opioids and the misleading marketing tactics of pharmaceutical companies has also spread. Multiple states and cities a
\hich\af44\dbch\af31505\loch\f44 re filing lawsuits against Purdue Pharma and other opioid producers.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 4 }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 In addition, more state governments are regulating the prescribing habits of doctors. At the same time however, rates of overdoses on heroin and fentanyl have increased suggesting that t
\hich\af44\dbch\af31505\loch\f44 hose who became addicted on prescription pills are now turning to illicit, stronger and more dangerous opiates.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 7}{
\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  This paper examines how Purdue Pharma and its partner Abbott laboratories engaged in deceptive and unethical marketing of OxyContin\'ae\loch\f44 
 that helpe\hich\af44\dbch\af31505\loch\f44 d spawn the current epidemic. 
\par }\pard \ltrpar\ql \li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\ul\insrsid7741077 
\par \hich\af43\dbch\af31505\loch\f43 Purdue\hich\f43 \rquote \loch\f43 s Claims for Low Addiction Risk in Patients with Chronic Pain Are Not Supported by Adequate Scientific Studies}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44  
\par 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 Beginning at least as early as 1997, Purdue\hich\f44 \rquote \loch\f44 
\hich\f44 s OxyContin\'ae\loch\f44  physician-directed promotional pieces, includin\hich\af44\dbch\af31505\loch\f44 \hich\f44 g advertisements, brochures and videos, contained the statement that \'93\loch\f44 \hich\f44 
less than 1% of patients taking opioids actually become addicted.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 8}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 \hich\f44  These marketing materials made the claim that the development of addiction to opioid medication is \'93\loch\f44 \hich\f44 rare.\'94\loch\f44  The OxyCont\hich\af44\dbch\af31505\loch\f44 \hich\f44 
in materials also characterized the statement that \'93\loch\f44 \hich\f44 opioid addiction (psychological dependence) is an important clinical problem in patients with moderate to severe pain treated with opioids,\'94\loch\f44 \hich\f44  as a \'93
\loch\f44 \hich\f44 myth.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 9}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
 This assertion significantly minimized the addict\hich\af44\dbch\af31505\loch\f44 ive potential of this new drug, and instead emphasized the purportedly minimal rate of addiction in chronic pain patients managed with existing opiates.
\par \hich\af44\dbch\af31505\loch\f44 \hich\f44 In fact, Purdue did not study the addictive potential of OxyContin\'ae\loch\f44 . Instead, the company relied on thr\hich\af44\dbch\af31505\loch\f44 
ee irrelevant, outdated studies to support its assertion that opiate treatment for chronic pain presented minimal risk of addiction.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 10-12 }{\rtlch\fcs1 
\af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 In the first study, Medina and Diamond}{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\insrsid7741077 \hich\af45\dbch\af31505\loch\f45  }{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 examined drug dependency among patients taking various medications for chronic \hich\af44\dbch\af31505\loch\f44 \hich\f44 
headaches. The study population was not comparable to patients on long term therapy with high potency, long acting opioids such as OxyContin\'ae\loch\f44 
 for chronic pain.  Instead, Medina and Diamond studied patients who were prescribed short-acting pain medications\hich\af44\dbch\af31505\loch\f44  \hich\af44\dbch\af31505\loch\f44 on an as-needed basis for relief of headaches.}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 10}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
 Only 62 of the 2,639 patients reviewed took narcotics, or a combination of analgesics and barbiturates, at least four times a week for at least six months.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 10}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  Of these 62 patients, 13 (19%) were dependent or \hich\af44\dbch\af31505\loch\f44 
abusers, based on definitions from the Diagnostics and Statistical Manual of Disorders.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 13}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\cf6\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 Only two of the 62 patients taking narcotics had taken an oxycodone product \hich\f44 \endash 
\loch\f44 \hich\f44  Percodan (5mg); none took OxyContin\'ae\loch\f44 \hich\f44 . This 19% rate of dependence and abuse is hardly \'93\loch\f44 r\hich\af44\dbch\af31505\loch\f44 \hich\f44 are\'94\loch\f44 \hich\f44  and is certainly not \'93\loch\f44 
\hich\f44 less than 1%\'94\loch\f44 \hich\f44  as Purdue asserted.  Moreover, this abuse/addiction rate occurred in patients taking PRN narcotics, which are much weaker (schedule III) than OxyContin\'ae\loch\f44  (schedule II)}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\cf6\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 . }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 In a conclusion that differed radically from Pu\hich\af44\dbch\af31505\loch\f44 
rdue\hich\f44 \rquote \loch\f44 \hich\f44 s, the original authors stated that their study revealed that \'93\loch\f44 \hich\f44 there is a danger of dependency and abuse in patients with chronic headaches.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 10}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  When Diamond was asked about Purdue\hich\f44 \rquote \loch\f44 s use of his study in a 2003 
}{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 New York Times }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 interview, he protested tha
\hich\af44\dbch\af31505\loch\f44 \hich\f44 t Purdue had mischaracterized his findings.  He stated that, \'93\loch\f44 [Purdue\hich\f44 \rquote \loch\f44 \hich\f44 
s characterization of addiction risk] distorts the picture and it clearly underplays the risk.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 14}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\insrsid7741077 
\par \hich\af44\dbch\af31505\loch\f44 In the second paper Purdue cited, Perry and Heidrich studied patients in pain undergoing\hich\af44\dbch\af31505\loch\f44  burn debridement.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 11}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
 Perry and Heidrich sent questionnaires to 151 burn facilities in the United States to review how burn pain is assessed and managed.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 11}{\rtlch\fcs1 
\af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  The physicians surveyed generally used lower doses of narcotics than those prescribed to OxyContin\'ae\loch\f44  p\hich\af44\dbch\af31505\loch\f44 \hich\f44 
atients for ailments that were far less painful than severe burns.  The focus of this study was not on addiction to pain medication or OxyContin\'ae\loch\f44 
, however, the survey did ask respondents if "any patient had become iatrogenically addicted" as a result of m\hich\af44\dbch\af31505\loch\f44 e\hich\af44\dbch\af31505\loch\f44 dical care.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 11}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  Twelve percent of 174 respondents stated that they knew of a \'93\loch\f44 
\hich\f44 patient who became a drug abuser upon discharge from the hospital as a result of receiving narcotic analgesics for burn pain.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 11}{
\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  The authors concluded that, among the over 10,000 c\hich\af44\dbch\af31505\loch\f44 
ases represented in the survey, not one patient became iatrogenically addicted.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 11}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44  Although 22 cases of addiction were noted, in all cases but one, the respondent reported that patients who became addicted had a prior history of drug abuse.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 11}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  This study provides little support for Purdue\hich\f44 \rquote \loch\f44 
s assertion that chronic narcotic use had a low addiction potential. Perry and Heidrich did not use any diagnostic criteria for addiction, nor did they collect patient data. Instead, the study was retrospecti\hich\af44\dbch\af31505\loch\f44 v
\hich\af44\dbch\af31505\loch\f44 \hich\f44 e, relying entirely on the memory of staff members, and none of the surveyed doctors used OxyContin\'ae\loch\f44 \hich\f44 
, which was not on the market at the time of the study.  Thus, the study provided no basis for comparison to current OxyContin\'ae\loch\f44  usage, nor could it support\hich\af44\dbch\af31505\loch\f44  \hich\af44\dbch\af31505\loch\f44 Purdue\hich\f44 
\rquote \loch\f44 s contention that pain patients treated with narcotics experience a low rate of addiction. 
\par \hich\af44\dbch\af31505\loch\f44 \hich\f44 Finally, to support its low risk of addiction claims for OxyContin\'ae\loch\f44 , Purdue relied on a 110-word letter to the editor of the New England Journal of Medicine,\hich\af44\dbch\af31505\loch\f44 
 written by Porter and Jick.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 12}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
 The letter, in its entirety, is as follows:
\par }\pard \ltrpar\ql \li720\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin720\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \loch\af44\dbch\af31505\hich\f44 \'93\loch\f44 
To the Editor: Recently, we examined our current files to determine the incidence of narcotic addiction in 39,946 hospitalized medical patients who were monitored consecutively. Al\hich\af44\dbch\af31505\loch\f44 
though there were 11,882 patients who received at least one narcotic preparation, there were only four cases of reasonably well documented addiction in patients who had no history of addiction. The addiction was considered major in only one instance. The 
\hich\af44\dbch\af31505\loch\f44 d\hich\af44\dbch\af31505\loch\f44 \hich\f44 
rugs implicated were meperidine in two patients, Percodan in one, and hydromorphone in one. We conclude that despite widespread use of narcotic drugs in hospitals, the development of addiction is rare in medical patients with no history of addiction.\'94}
{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 12}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 Th\hich\af44\dbch\af31505\loch\f44 ere are several problems with Purdue
\hich\f44 \rquote \loch\f44 \hich\f44 s reliance on this letter.  First, this retrospective analysis does not include a single patient who was prescribed a controlled-release oxycodone product like OxyContin\'ae\loch\f44 
.  Later, insworn testimony, Dr. Jick stated tha\hich\af44\dbch\af31505\loch\f44 t\hich\af44\dbch\af31505\loch\f44 \hich\f44 , \'93\loch\f44 We don\hich\f44 \rquote \loch\f44 \hich\f44 t have any information in this letter which relates to these \'93
\loch\f44 \hich\f44 [people taking OxyContin\'ae\loch\f44 \hich\f44 .]\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 9}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44  Only 450 of the nearly 12,000 patients reviewed took an oxycodone product, and at least one of the four addiction cases identified involved a patient who \hich\af44\dbch\af31505\loch\f44 took such a product: Percodan.}{
\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 15}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
 The largest dose of oxycodone in Percodan is equivalent to the lowest recommended dose of OxyContin\'ae\loch\f44 .  
\par \hich\af44\dbch\af31505\loch\f44 As is the case with the other studies Purdue cited, the patients Porter and Jick studied bear little resemblance to tho\hich\af44\dbch\af31505\loch\f44 \hich\f44 se likely to be prescribed OxyContin\'ae\loch\f44 
. Porter and Jick studied hospitalized patients who may have received as little as one narcotic pill or shot, generally used the drug for a brief time, and had the drug administered by hospital personnel. Porter and Ji\hich\af44\dbch\af31505\loch\f44 c
\hich\af44\dbch\af31505\loch\f44 k did not follow patients after discharge.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 15}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44  Thus, the study could not reliably detect addiction, which develops over time after repeated use, nor could the study address the arguably higher addiction risk in unsupervised ambulatory outpatients, who are th
\hich\af44\dbch\af31505\loch\f44 \hich\f44 ose most likely to use a controlled-release opiate on an extended basis. The Porter and Jick study did not mention of OxyContin\'ae\loch\f44  at all, and it couldn\hich\f44 \rquote \loch\f44 \hich\f44 
t because it was completed twenty-five years before OxyContin\'ae\loch\f44 \hich\f44  was sold.  Most OxyContin\'ae\loch\f44  patients self-\hich\af44\dbch\af31505\loch\f44 m\hich\af44\dbch\af31505\loch\f44 
edicate at home, outside of  the healthcare setting, where they can alter both the prescribed dose and dose schedule, alterations which increase addiction potential, and which only rarely occur in the hospital setting. Much like Perry and Heidrich, Porter
\hich\af44\dbch\af31505\loch\f44  \hich\af44\dbch\af31505\loch\f44 and Jick did not rely on standard DSM criteria to diagnose addiction, but instead based their results on the presence or absence of a written diagnosis of addiction in doctors\hich\f44 
\rquote \loch\f44  or nurses\hich\f44 \rquote \loch\f44  notes in patient files.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 15,16}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44  This}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf2\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
is likely to have resulted in an u\hich\af44\dbch\af31505\loch\f44 \hich\f44 nder-recording of the \'93\loch\f44 \hich\f44 addiction\'94\loch\f44  diagnosis. With these glaring methodological flaws, Jick\hich\f44 \rquote \loch\f44 \hich\f44 
s study should never have been used to support the contention that addiction in pain patients (including OxyContin\'ae\loch\f44 \hich\f44  patients) is \'93\loch\f44 \hich\f44 rare.\'94\loch\f44  
\par \hich\af44\dbch\af31505\loch\f44 In contrast to these unfoun\hich\af44\dbch\af31505\loch\f44 
ded assertions of opioid safety, Purdue failed to inform  physicians of several studies that indicate high rates of opioid addiction for chronic pain patients. In 1992, Fishbain et al found rates of addiction of 3.2%-18.9% in their meta-analysis of the sc
\hich\af44\dbch\af31505\loch\f44 i\hich\af44\dbch\af31505\loch\f44 entific literature on chronic pain patients.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 17}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  These percentages were reiterated by Barry Dickinson in a 2000 review article for the American Medical Association Council on Scientific Affairs.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 18}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  Addiction rates of 3 to 19 percent}{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 
\b\f43\fs24\insrsid7741077 \hich\af43\dbch\af31505\loch\f43  }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 cannot be considered \'93\loch\f44 rare\loch\af44\dbch\af31505\hich\f44 .\'94}{
\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 17}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
 A review of the literature on chronic pain and addiction reveals that numerous papers document  rates of addiction between 3 and 34 percent in chronic pain patients.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 17,19-23
\par }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 Nonetheless, for several years, Purdue ignored contrary data and used three i\hich\af44\dbch\af31505\loch\f44 \hich\f44 
nappropriate, flawed studies in their marketing materials to support their contention that addiction in chronic pain patients receiving opiates is \'93\loch\f44 \hich\f44 less than one percent\'94\loch\f44 \hich\f44  or \'93\loch\f44 \hich\f44 rare.\'94}{
\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 10-12,24,25}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
  In 2001, the FDA concluded that these references did not suppo\hich\af44\dbch\af31505\loch\f44 rt Purdue\hich\f44 \rquote \loch\f44 \hich\f44 s assertion of low risk, and  required the company to change OxyContin\'ae\rquote \loch\f44 \hich\f44 
s patient package insert wording from \'93\loch\f44 Iatrogenic \hich\f44 \lquote \loch\f44 addiction\hich\f44 \rquote \loch\f44 \hich\f44  to opioids legitimately used in the management of pain is very rare\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 26}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  to \'93\loch\f44 data are not available to establish t
\hich\af44\dbch\af31505\loch\f44 \hich\f44 he true incidence of addiction.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 27}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 \hich\f44  Unfortunately, this FDA-ordered \'93\loch\f44 \hich\f44 correction\'94\loch\f44 
 occurred years after it had approved the original wording, long after the original misleading label was in the hands of millions of patients and prescribers.
\par \hich\af44\dbch\af31505\loch\f44 Purdue\hich\f44 \rquote \loch\f44 s use of th\hich\af44\dbch\af31505\loch\f44 ese irrelevant studies should have ended after the  FDA admonishment in 2001.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 28}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
 However, Purdue personnel continued to rely on at least one of these studies and continued to assert that addiction to OxyContin\'ae\loch\f44 \hich\f44  is \'93\loch\f44 \hich\f44 rare.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 29}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  In 2003, Dr. Curtis Wright, Purdu\hich\af44\dbch\af31505\loch\f44 e\hich\f44 \rquote 
\loch\f44 \hich\f44 s Executive Director in Risk Assessment Coordination for New Products, testified that he still believed addiction to OxyContin\'ae\loch\f44  is rare.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 29}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44   Dr. Wright based his opinion on the Agency for HealthCare Policy and Research (AHCPR) guidelines, which in turn re
\hich\af44\dbch\af31505\loch\f44 lied on the Porter and Jick letter.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 29}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 \hich\f44  Tellingly, the AHCPR guidelines themselves state that they are \'93\loch\f44 \hich\f44 no longer viewed as guidance for current medical practice.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 30}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44   Dr. Wright  served as the FDA medical reviewer for OxyContin\'ae\loch\f44 
 prior to being hired by Purdu\hich\af44\dbch\af31505\loch\f44 e.  Given the serious problems with Purdue\hich\f44 \rquote \loch\f44 s OxyContin label misrepresentations and its aggressive marketing practices, Dr. Wright\hich\f44 \rquote \loch\f44 
\hich\f44 s transition from OxyContin\'ae\loch\f44  FDA approval-reviewer to Purdue executive raises important questions about industry influence a\hich\af44\dbch\af31505\loch\f44 n\hich\af44\dbch\af31505\loch\f44 \hich\f44 d the problems of the \'93
\loch\f44 \hich\f44 revolving door\'94\loch\f44  between government agencies and the industries they are supposed to regulate.\tab 
\par }\pard \ltrpar\ql \li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\insrsid7741077 
\par }{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\ul\insrsid7741077 \hich\af43\dbch\af31505\loch\f43 Purdue\hich\f43 \rquote \loch\f43 s Inadequate Warnings for Addiction Risk on Patient Package Inserts
\par 
\par }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  \tab From 1997 to 2001, Purdue\hich\f44 \rquote \loch\f44 \hich\f44 s product labeling for OxyContin\'ae\hich\af44\dbch\af31505\loch\f44 
 failed to adequately warn about potential abuse or addiction.  Purdue failed to include addiction warnings in the label\hich\f44 \rquote \loch\f44 \hich\f44 s \'93\loch\f44 \hich\f44 Warning,\'94\loch\f44 \hich\f44  \'93\loch\f44 \hich\f44 Precautions,
\'94\loch\f44 \hich\f44  and \'93\loch\f44 \hich\f44 Information for Patients/Caregivers\'94\loch\f44  sections; omitted contraindication warnings for people with prio\hich\af44\dbch\af31505\loch\f44 r\hich\af44\dbch\af31505\loch\f44 
 drug addiction; and neglected to list any symptoms of opioid withdrawal.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 26,31-34
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 The inadequacy of the OxyContin\'ae\loch\f44 
 warning label is further underscored when compared to other addictive oral controlled-release opioid analgesics containing morphine sulfate. \hich\af44\dbch\af31505\loch\f44 \hich\f44 
 MS Contin (Purdue Frederick) and OraMorph SR (Roxanne) were similarly marketed as controlled-release 12-hour pain control products, in addition to being Schedule II drugs. At the time, the MS Contin label stated that \'93\loch\f44 
psychological and physical dependenc\hich\af44\dbch\af31505\loch\f44 e\hich\af44\dbch\af31505\loch\f44 \hich\f44  may develop upon repeated administration.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 35}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  The OxyContin\'ae\loch\f44 
 label, on the other hand, did not directly acknowledge the risk of narcotic dependence. Despite Purdue\hich\f44 \rquote \loch\f44 \hich\f44 s authorship of both labels, the MS Contin and OxyContin\'ae\loch\f44  labels were strikingly different. 
\hich\af44\dbch\af31505\loch\f44 \hich\f44 When OxyContin\'ae\loch\f44  was released onto the market, its label should have at least mirrored the MS Contin label, reflecting the significant risk of dependence or addiction.
\par \hich\af44\dbch\af31505\loch\f44 \hich\f44 The OraMorph SR\'ae\loch\f44 \hich\f44  (Roxanne) label acknowledged the addiction risk even more clearly: \'93\loch\f44 Morp\hich\af44\dbch\af31505\loch\f44 
hine is the most commonly cited prototype for a narcotic substance that possesses an addiction-forming or addiction-sustaining liability.  A patient may be at risk for developing dependence to morphine if used improperly or for overly long periods of time
.\loch\af44\dbch\af31505\hich\f44 \'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 36}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
  Unlike the OxyContin\'ae\loch\f44 \hich\f44  label, the OraMorph SR\'ae\loch\f44 \hich\f44  label alerted physicians that, \'93\loch\f44 
Individuals with a history of opioid or other substance abuse or dependence, being more apt to respond to euphorigenic and reinforcing properties of morphine, would be consi\hich\af44\dbch\af31505\loch\f44 \hich\f44 dered to be at greater risk.\'94}{
\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 36}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44   Also, unlike the OxyContin\'ae\loch\f44 
\hich\f44  label, the OraMorph SR\'ae\loch\f44  label did not undermine its addiction warning by citing the product\hich\f44 \rquote \loch\f44 \hich\f44 s delayed absorption characteristics or by proclaiming that \'93\loch\f44 \hich\f44 reports\'94
\loch\f44 \hich\f44  of addiction are \'93\loch\f44 \hich\f44 rare.\'94
\par \hich\af44\dbch\af31505\loch\f44 Addition\hich\af44\dbch\af31505\loch\f44 ally, there were significant discrepancies between Purdue\hich\f44 \rquote \loch\f44 
s United States OxyContin label warnings and its foreign warnings for the same product.  The Austria Codex, (Austria\hich\f44 \rquote \loch\f44 s information system for specialties information about all medicines registered 
\hich\af44\dbch\af31505\loch\f44 i\hich\af44\dbch\af31505\loch\f44 n Austria) illustrates these discordant warnings.  Unlike Purdue\hich\f44 \rquote \loch\f44 \hich\f44 s warning in the United States that suggested that OxyContin\'ae\loch\f44 
 can be used for moderate to severe pain, Mundipharma (a corporation tied to Purdue Pharma}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 37}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 ) in Austria, stated that OxyContin\'ae\loch\f44  i\hich\af44\dbch\af31505\loch\f44 \hich\f44 s only be used for the \'93\loch\f44 \hich\f44 treatment of severe pain.\'94}{\rtlch\fcs1 
\af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 31}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
 Additionally, the package insert in Austria differentiated between indications for nonmalignant and cancer pain.  For nonmalignant pain the insert stated: \'93\loch\f44 \hich\f44 Treatment with OxyContin\'ae\loch\f44  should be brief and s
\hich\af44\dbch\af31505\loch\f44 \hich\f44 hould be temporarily interrupted to minimize the risk of dependence\'94.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 38}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  The Austrian version also reiterated the risk of addiction in the \'93\loch\f44 \hich\f44 Side Effects\'94\loch\f44 \hich\f44  section, stating  that \'93\loch\f44 \hich\f44 
habit forming may occur in patients who are administered OxyContin\'ae\'94.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 38}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44  The pac\hich\af44\dbch\af31505\loch\f44 \hich\f44 kage insert in the United States for 2003 failed to clearly acknowledge that OxyContin\'ae\loch\f44 
 is an addictive drug and that addiction is a significant risk when the drug is taken as prescribed for an extended period of time, for both malignant and non-malignant\hich\af44\dbch\af31505\loch\f44  \hich\af44\dbch\af31505\loch\f44 pain.}{\rtlch\fcs1 
\af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 27
\par }\pard \ltrpar\ql \li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\par }{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\ul\insrsid7741077 \hich\af43\dbch\af31505\loch\f43 Purdue\hich\f43 \rquote \loch\f43 s Osteoarthritis Indication
\par }{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\insrsid7741077 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
In a remarkable marketing and anti-regulatory maneuver, Purdue expanded the indications for Schedule II OxyContin\'ae\loch\f44 
 from the narrow market of malignancy sufferers, to the much larger market of musculoskeletal pain sufferers. At inception of the FDA approva\hich\af44\dbch\af31505\loch\f44 l\hich\af44\dbch\af31505\loch\f44 \hich\f44 
 process in the early 1990s, Purdue desired FDA approval for OxyContin\'ae\loch\f44  use in patients with arthritis.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 39}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  But in March 1993, the FDA medical reviewer for OxyContin\'ae\loch\f44 \hich\f44 , Dr. Curtis Wright alerted the Purdue OxyContin\'ae\loch\f44 
 project team that others at the FDA felt O\hich\af44\dbch\af31505\loch\f44 \hich\f44 xyContin\'ae\loch\f44 
 was not appropriate for patients suffering from osteoarthritis.  Dr. Wright told Purdue that the FDA would not even approve a protocol designed to test the effectiveness of opioids in osteoarthritis treatment.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 29}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  To circumvent this objection, Wrig\hich\af44\dbch\af31505\loch\f44 
ht suggested that Purdue could overcome the FDA objections by re-writing the protocol to state that osteoarthritis patients were being used as a pain model.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 29 }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 Once the study was complete, Purdue successfully circumvented the FDA\hich\f44 \rquote \loch\f44 
s initial negative position\hich\af44\dbch\af31505\loch\f44 , and used it to market the drug for osteoarthritis.    
\par \hich\af44\dbch\af31505\loch\f44 \hich\f44 In 1999, Purdue expanded this indication beyond osteoarthritis and began promoting OxyContin\'ae\loch\f44 \hich\f44 
 for arthritis sufferers in general. For example, Purdue captioned one advertisement for OxyContin\'ae\loch\f44  with t\hich\af44\dbch\af31505\loch\f44 \hich\f44 he slogan, \'93\loch\f44 \hich\f44 Proven Effective in Arthritis Pain.\'94}{\rtlch\fcs1 
\af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 40}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
 The FDA took notice of a subsequent Purdue advertisement in May of 2000, and reprimanded the company for this misleading claim. In a letter to Purdue, the FDA explained, \'93\'85\hich\af44\dbch\af31505\loch\f44 \hich\f44 
your journal ad is misleading because it suggests that OxyContin\'ae\loch\f44 \hich\f44  can be used as a first-line therapy for the treatment of arthritis when such has not been demonstrated by substantial evidence\'85\loch\f44 
You should immediately discontinue the use of this journal adv\hich\af44\dbch\af31505\loch\f44 e\hich\af44\dbch\af31505\loch\f44 \hich\f44 rtisement.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
41}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44   However, in their 2001 Budget Plan, Purdue outlined a strategy to continue to promote OxyContin\'ae\loch\f44 
 to specialists in rheumatology, and to other practitioners dealing with arthritis and musculoskeletal pain.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 42  }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 Pursuing this policy of promoting\hich\af44\dbch\af31505\loch\f44  an off-label or unapproved use is a violation of industry standards. 
\par 
\par }\pard \ltrpar\ql \li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\ul\insrsid7741077 \hich\af43\dbch\af31505\loch\f43 Purdue\hich\f43 \rquote \loch\f43 \hich\f43 s \'93\loch\f43 \hich\f43 
Revised Label\'94\loch\f43  Is Still Inadequate and Misleading
\par }{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\insrsid7741077 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
In July of 2001, the FDA recognized additional deficienciess in the OxyContin\'ae\loch\f44  label after receiving numerous reports of ab\hich\af44\dbch\af31505\loch\f44 use and drug-related deaths.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 28}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
 The FDA warned Purdue that it had failed to adequately publicize the dangers of OxyContin\'ae\loch\f44 , and demanded that the drug company revise its insert language.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 28}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  Although Purdue complied with the FDA\hich\f44 \rquote \loch\f44 s demands and revised its labe
\hich\af44\dbch\af31505\loch\f44 l, the changes created additional problems.
\par \hich\af44\dbch\af31505\loch\f44 \hich\f44 By 2002, the FDA and the media had become greatly concerned over the illicit use of OxyContin\'ae.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 43}{
\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  Purdue took advantage of this concern, and altered the label to make it appear as though illegal use and abuse wer\hich\af44\dbch\af31505\loch\f44 \hich\f44 
e the only addiction-related problems associated with OxyContin\'ae\loch\f44 \hich\f44  use: \'93\loch\f44 \hich\f44 
Oxycodone can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing OxyContin\'ae\loch\f44  in situations where the phys\hich\af44\dbch\af31505\loch\f44 i
\hich\af44\dbch\af31505\loch\f44 \hich\f44 cian or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 44}{\rtlch\fcs1 
\af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  Purdue ignored the far larger population of patients who could suffer from addiction just by taking their recommended dose. Given the commercial success of OxyContin
\loch\af44\dbch\af31505\hich\f44 \'ae\loch\f44 \hich\f44 , legal use will engender a large number of addicts, even if the addiction rate is \'93\loch\f44 \hich\f44 far less than 1%.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 8
\par }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 Despite the increasing availability of information on how OxyContin\'ae\loch\f44 
 marketing had increased prescribing to inappropriate patients, in revising its lab\hich\af44\dbch\af31505\loch\f44 \hich\f44 
el, Purdue failed to address most of the important addiction issues, and neglected to mention that the drug can be abused and can cause addiction in its intact orally-administered form, even when taken as prescribed. The new label stated that: \'93
\loch\f44 The develo\hich\af44\dbch\af31505\loch\f44 p\hich\af44\dbch\af31505\loch\f44 \hich\f44 
ment of addiction to opioid analgesics in properly managed patients with pain has been reported to be rare.  However, data are not available to establish the true incidence of addiction in chronic pain patients.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 27}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  These statements are contradictory on the\hich\af44\dbch\af31505\loch\f44 \hich\f44 
ir face: if data are not available, how can the rate of addiction be \'93\loch\f44 \hich\f44 reported to be rare\'94\loch\f44 ?  }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \loch\af44\dbch\af31505\hich\f44 \u8232\'3f}{\rtlch\fcs1 
\af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \tab \hich\af44\dbch\af31505\loch\f44 Purdue\hich\f44 \rquote \loch\f44 
s revised label tried to create an artificial distinction between physical dependence and addiction, when in fact significant overlap occurs.  The label s\hich\af44\dbch\af31505\loch\f44 \hich\f44 tated, \'93\loch\f44 \hich\f44 
Abuse and addiction are separate and distinct from physical dependence and tolerance.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 44}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  This is not true.  While drug tolerance and physical dependence without addiction may occur with pain treatment, these symptoms are also well-recognized diagno\hich\af44\dbch\af31505\loch\f44 
stic symptoms of opiate dependence.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 45}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
 Resolving the question of whether addiction is present in a non-malignant pain patient presenting with drug tolerance, withdrawal, and physical dependence is not an easy matter for the practicing physician, but Purdue \hich\af44\dbch\af31505\loch\f44 
made the distinction appear clear and straightforward. Unfortunately, Purdue conveyed a false sense of security that the non-malignant chronic pain patient who is ever-demanding of more and stronger narcotic medications is merely a predictable example of 
\loch\af44\dbch\af31505\hich\f44 \'93\hich\af44\dbch\af31505\loch\f44 \hich\f44 pseudo-addiction\'94\loch\f44  (inadequate dosing, leading to requests for stronger doses), innocuous tolerance, or the expected physical dependence on opiates.}{\rtlch\fcs1 
\af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 46}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
 Physicians were thus discouraged from considering these demands as signs of \'93\loch\f44 \hich\f44 real\'94\loch\f44  addiction, and instead \hich\af44\dbch\af31505\loch\f44 were encouraged to increase the dose of OxyContin. 
\par }\pard \ltrpar\ql \li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\par }{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\ul\insrsid7741077 \hich\af43\dbch\af31505\loch\f43 Purdue Exploits the New FDA-Approved Label to Expand Its Market}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44  
\par 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
The FDA was concerned that Purdue had used its label to inappropriately broaden the indications for use of OxyContin\'ae\loch\f44  while understating \hich\af44\dbch\af31505\loch\f44 \hich\f44 
the risks of abuse. After negotiations with the FDA, Purdue revised its OxyContin\'ae\loch\f44  label in 2002 to include a black box warning\hich\f44 \emdash \loch\f44 the strongest warning found on prescription drugs\hich\f44 \emdash \loch\f44 \hich\f44 
regarding abuse risks, and a new section on \'93\loch\f44 Misuse, Abuse, And Diversion of \hich\af44\dbch\af31505\loch\f44 O\hich\af44\dbch\af31505\loch\f44 \hich\f44 pioids.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 44}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
 Although the FDA was under the impression that the revisions would narrow the indications, Purdue saw the change as an opportunity to further \'93\loch\f44 \hich\f44 broaden OxyContin\'ae\loch\f44 \hich\f44  Tablets usage in the management of pain,\'94
\loch\f44  with special emphasis on post-operative p\hich\af44\dbch\af31505\loch\f44 ain.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 47}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  Purdue recognized that they could transform the FDA\hich\f44 \rquote \loch\f44 \hich\f44 s reprimand into a marketing advantage with \'93\loch\f44 \hich\f44 enormous opportunities.\'94}{
\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 47}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  The black box warning stated that OxyContin
\'ae\loch\f44 \hich\f44  should be restricted to patients \'93\loch\f44 with moderate to severe pain when a continuous\hich\af44\dbch\af31505\loch\f44 \hich\f44 , around-the-clock analgesic is needed for an extended period of time.\'94}{\rtlch\fcs1 
\af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 27}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  Purdue\hich\f44 \rquote \loch\f44 \hich\f44 
s 2002 Budget Plan explained how they intended to take advantage of this new language, \'93\loch\f44 \hich\f44 The action taken by the FDA to clarify the OxyContin\'ae\loch\f44  Tablet labeling has created enorm\hich\af44\dbch\af31505\loch\f44 \hich\f44 
ous opportunities. In effect, the FDA has expanded the indication for OxyContin\'ae\loch\f44 \hich\f44  Tablets to any patient with moderate to severe around the clock persistent pain\'85.\'94\loch\f44 \hich\f44  The Budget Plan went on to proclaim that, 
\'93\loch\f44 This broad labeling is likely to never again be \hich\af44\dbch\af31505\loch\f44 a\hich\af44\dbch\af31505\loch\f44 \hich\f44 vailable for an opioid seeking FDA approval. This may give OxyContin\'ae\loch\f44 \hich\f44 
 Tablets a competitive advantage.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 47}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
 Thus, Purdue seized on the FDA label change to greatly expand the market for OxyContin\'ae\loch\f44 , a Schedule II opioid narcotic, as a first line agent for the \hich\af44\dbch\af31505\loch\f44 
relief of moderate pain, a distinction previously reserved for Schedule III and IV narcotics and non- Scheduled alternatives like NSAIDS and Tramadol. This marketing strategy, promoted to prescribing physicians, further increased the risk of addiction for
\hich\af44\dbch\af31505\loch\f44  \hich\af44\dbch\af31505\loch\f44 \hich\f44 patients. Instead of receiving lower potency, combination schedule III drugs, patients would receive much stronger OxyContin\'ae\loch\f44 \hich\f44  for their \'93\loch\f44 
\hich\f44 moderate\'94\loch\f44  pain.  Thus, Purdue used an FDA citation, meant to limit use, to gain exclusive access to a new, much larger\hich\af44\dbch\af31505\loch\f44  \hich\af44\dbch\af31505\loch\f44 \hich\f44 
class of users as it promoted OxyContin\'ae\loch\f44  as a substitute for less addictive alternatives.
\par }\pard \ltrpar\ql \li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\par }{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\ul\insrsid7741077 \hich\af43\dbch\af31505\loch\f43 Purdue\hich\f43 \rquote \loch\f43 s Marketing and Advertising Campaign:  Downplaying Addiction Risk to Patients and Physicians
\par }{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\insrsid7741077 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 Although Purdue claims it did not do direct-to-consumer marketin
\hich\af44\dbch\af31505\loch\f44 g, it directed a great deal of its marketing directly to patients via brochures, videos, advertisements and the internet.}{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\insrsid7741077 \hich\af43\dbch\af31505\loch\f43 
  }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 These promotional activities encouraged OxyContin\'ae\loch\f44  use in a wide range of patients, while underplaying the risks of the drug. At the 
\hich\af44\dbch\af31505\loch\f44 \hich\f44 time, Purdue did appear to provide information to doctors and consumers through an apparently independent entity called \'93\loch\f44 \hich\f44 Partners Against Pain,\'94\loch\f44 \hich\f44 
 which claimed it was as an \'93\loch\f44 \hich\f44 alliance of patients, caregivers and health care providers.\'94\loch\f44  However, this was an \hich\af44\dbch\af31505\loch\f44 e\hich\af44\dbch\af31505\loch\f44 \hich\f44 xample of an \'93\loch\f44 
\hich\f44 AstroTurf\'94\loch\f44 \hich\f44  or fake grass roots organization that Purdue owned and operated.  Purdue itself published and copyrighted the \'93\loch\f44 \hich\f44 Partners Against Pain\'94\loch\f44  website}{\rtlch\fcs1 \ab\af43\afs24 
\ltrch\fcs0 \b\f43\fs24\cf11\insrsid7741077 ,}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  and the written materials on the site represented the interests and viewpoints of its ow
\hich\af44\dbch\af31505\loch\f44 \hich\f44 ner.  Purdue used the site to promote its unsupported views about the risks of addiction associated with OxyContin\'ae\loch\f44 \hich\f44 . For example, a \'93\loch\f44 \hich\f44 Frequently Asked Questions\'94
\loch\f44  booklet available from the site, titled "A Guide to Your New Pain Medication and How to Become\hich\af44\dbch\af31505\loch\f44  \hich\af44\dbch\af31505\loch\f44 \hich\f44 a Partner Against Pain,\'94\loch\f44 \hich\f44 
 reassures readers that OxyContin\'ae\loch\f44  only rarely presents an addiction risk.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 48}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 \hich\f44  One question asks, \'93\loch\f44 \hich\f44 Aren't opioid pain medications like OxyContin\'ae\loch\f44  Tablets "addicting"? Even my family is concerned about this." Purdue proffered the follo
\hich\af44\dbch\af31505\loch\f44 wing misinformation as its answer:
\par }\pard \ltrpar\ql \li720\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin720\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \loch\af44\dbch\af31505\hich\f44 \'93\loch\f44 \hich\f44 Drug addiction means using a drug to get \'93
\loch\f44 \hich\f44 high\'94\loch\f44 \hich\f44  rather than to relieve pain. You are taking opioid pain medication for medical purposes. The medical purposes are clear and the effects are beneficial, not harmful.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 48}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 Thi\hich\af44\dbch\af31505\loch\f44 \hich\f44 
s "guide to patients" misleads patients into believing that their motivation for taking OxyContin\'ae\loch\f44 
 (i.e., for pain instead of to "get high") is the major determinant of whether they are, or will become, addicted to the medication. Yet, as is the case with\hich\af44\dbch\af31505\loch\f44  \hich\af44\dbch\af31505\loch\f44 \hich\f44 
all opiates, some patients will become addicted even if they initially used the drug to relieve pain and not to \'93\loch\f44 \hich\f44 get high.\'94\loch\f44  There is no scientific support for the notion that the user\hich\f44 \rquote \loch\f44 
s motivation for initially using opiates determines whether he or she w\hich\af44\dbch\af31505\loch\f44 i\hich\af44\dbch\af31505\loch\f44 
ll become addicted later. In fact, a great many patients become addicted when exposed long enough to narcotics taken initially for legitimate medical reasons.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 17}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  
\par \hich\af44\dbch\af31505\loch\f44 \hich\f44 In 2001, in another question and answer section of the \'93\loch\f44 \hich\f44 Partners Against Pain\'94\loch\f44  website, Purdue\hich\af44\dbch\af31505\loch\f44 \hich\f44  declared: \'93\loch\f44 \hich\f44 
When you feel pain, your pain is real\'85\loch\f44 \hich\f44  Remember: You have every right to ask [doctors and nurses] to help you relieve the pain as much as possible.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 49}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  By implying that patients have a right to as much pain relief as they wish without any regard
\hich\af44\dbch\af31505\loch\f44  for prescriber objections or for  possible adverse reactions, Purdue encouraged patients to demand  its drug, and propagated misinformation about pain perception and  risk of addiction.
\par \hich\af44\dbch\af31505\loch\f44 In 1986, the World Health Organization developed practice guidelines \hich\af44\dbch\af31505\loch\f44 for cancer pain management and recommended that treatment begin with non-opioid analgesics.}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 50}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
 Purdue cited the WHO guidelines in their own marketing materials; however, Purdue altered the WHO\hich\f44 \rquote \loch\f44 \hich\f44 s position with the marketing slogan \'93\loch\f44 \hich\f44 the one to start with,\'94\loch\f44  wh
\hich\af44\dbch\af31505\loch\f44 ich}{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\insrsid7741077 \hich\af43\dbch\af31505\loch\f43  }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
positioned OxyContin\'ae\loch\f44  as the first drug of choice for pain.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 24,51}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\par \hich\af44\dbch\af31505\loch\f44 \hich\f44 Purdue provided questionable advice to patients in a pamphlet and informational video, both titled, \'93\loch\f44 \hich\f44 From One Pain Patient to Another,\'94\loch\f44 
 which encouraged patients to doctor-shop to find pr\hich\af44\dbch\af31505\loch\f44 \hich\f44 oviders who were most willing to prescribe narcotics. Purdue told patients, \'93\loch\f44 Don\hich\f44 \rquote \loch\f44 t be afraid about the things you
\hich\f44 \rquote \loch\f44 \hich\f44 ve heard about these drugs [opioids],\'94\loch\f44 \hich\f44  and, \'93\loch\f44 \hich\f44 ...find the right doctor.\'94\loch\f44 \hich\f44  One \'93\loch\f44 \hich\f44 patient\'94\loch\f44 \hich\f44 
 featured in the video remarked, \'93\loch\f44 I think it is very unf\hich\af44\dbch\af31505\loch\f44 o\hich\af44\dbch\af31505\loch\f44 \hich\f44 
rtunate that so many physicians are reluctant to treat people like me, who have moderate chronic pain, with opioids.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 25}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  Another patient was shown being treated with 1200 mg of OxyContin\'ae\loch\f44  per day! Purdue thus disparaged the more cautious prescribing practic
\hich\af44\dbch\af31505\loch\f44 es of responsible health practitioners who approached}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf6\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 this drug as potentially addictive.
\par \hich\af44\dbch\af31505\loch\f44 
Purdue continued to target physicians with promotional pieces that misrepresented scientific information on addiction. Starting on January 8, 2001, Purdue implemented a promotional letter campaign to physicians citing the Porter and Jick letter:
\par }\pard \ltrpar\ql \li720\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin720\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \loch\af44\dbch\af31505\hich\f44 \'93\loch\f44 The risk \hich\af44\dbch\af31505\loch\f44 
of addiction to opioids in clinical care has been greatly exaggerated.  Experts in pain currently define addiction as, \hich\f44 \lquote \'85\loch\f44  the compulsive use of a drug for non-medical purposes, usually with harm to the individual.\hich\f44 
\rquote \loch\f44  Very few patients taking opioids for pai\hich\af44\dbch\af31505\loch\f44 n\hich\af44\dbch\af31505\loch\f44 
 fit this description. In fact, a survey of more than 11,000 opioid using patients, taken over several years, found only four cases of documented addiction...it\hich\f44 \rquote \loch\f44 \hich\f44 
s important to allay any fears patients may have about taking opioids.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 52}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44    
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 Purdue clung to it\hich\af44\dbch\af31505\loch\f44 \hich\f44 
s claim, despite the fact that Dr. Jick has disavowed the relevance of his study to OxyContin\'ae\loch\f44  patients.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 15,53}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\insrsid7741077 
\par \hich\af44\dbch\af31505\loch\f44 \hich\f44 Purdue also promoted OxyContin\'ae\loch\f44  as a substitute for less addictive, safer pain medications.  In their 1997 Budget Plan they explained, 
\par }\pard \ltrpar\ql \li720\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin720\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \loch\af44\dbch\af31505\hich\f44 \'93\loch\f44 When an o\hich\af44\dbch\af31505\loch\f44 \hich\f44 pioid na
\'ef\loch\f44 \hich\f44 ve patient needs an opioid analgesic, physicians are reluctant to begin them on MS Contin.  Therefore, OxyContin\'ae\loch\f44 \hich\f44 
 is the one to start with for patients who would otherwise be started on Percocet, Lortab, Vicodin or Tylenol #3.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 54}{\rtlch\fcs1 \ab\af43\afs24 
\ltrch\fcs0 \b\f43\fs24\cf11\insrsid7741077 \hich\af43\dbch\af31505\loch\f43  }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
All of these drugs are narcotics, but none have the same addictive potential as OxyContin\'ae\loch\f44 
, as they combine low doses of oxycodone or codeine with either aspirin or acetaminophen. Their dosing is limited by side effects of the anti-inflammatory or acetami\hich\af44\dbch\af31505\loch\f44 n\hich\af44\dbch\af31505\loch\f44 
ophen component of the pill}{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\cf11\insrsid7741077 ,}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
 and they are less subject to abuse through pill crushing or chewing.  Purdue\hich\f44 \rquote \loch\f44 \hich\f44 s marketing of OxyContin\'ae\loch\f44 
, a single-entity narcotic with higher doses of 10, 20, 40, 80, or 160 (removed from market) milligrams of oxycodone as a pre\hich\af44\dbch\af31505\loch\f44 ferred alternative to these lower strength narcotics, put patients at higher risk for addiction.

\par }\pard \ltrpar\ql \li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  
\par }{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\ul\insrsid7741077 \hich\af43\dbch\af31505\loch\f43 Purdue\hich\f43 \rquote \loch\f43 s Unbalanced Ad Campaign
\par 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 Purdue\hich\f44 \rquote \loch\f44 \hich\f44 
s questionable marketing strategy continued with unbalanced journal advertisements. An October 2002, an OxyContin\'ae\loch\f44  ad\hich\af44\dbch\af31505\loch\f44 vertisement in the }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\insrsid7741077 
\hich\af45\dbch\af31505\loch\f45 Journal of the American Medical Association (JAMA)}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  stated, \'93\loch\f44 WHEN IT\hich\f44 \rquote \loch\f44 
\hich\f44 S TIME TO CONSIDER Q4-6H OPIOIDS\'85\loch\f44 \hich\f44 REMEMBER, EFFECTIVE RELIEF TAKES JUST TWO.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 55}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  Purdue failed to include information on the abuse potential of opioids in the body of the \hich\af44\dbch\af31505\loch\f44 \hich\f44 
advertisement.  It did, however, use some advertising space to explain a few of the side effects, including, \'93\loch\f44 \hich\f44 constipation, nausea, sedation, dizziness, vomiting, pruritus, headache, dry mouth, sweating and weakness,\'94\loch\f44 
 but the ad had no mention of abuse, a\hich\af44\dbch\af31505\loch\f44 d\hich\af44\dbch\af31505\loch\f44 diction, diversion or death.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 55}{\rtlch\fcs1 
\af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  A November 13, 2002 OxyContin\'ae\loch\f44  advertisement also featured in the }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\insrsid7741077 
\hich\af45\dbch\af31505\loch\f45 Journal of the American Medical Association (JAMA)}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  showed a man and a boy fishing with the prominent headline, \'93
\loch\f44 \hich\f44 THERE CAN BE LIFE WITH RELIEF.\'94\loch\f44  The ad also dep\hich\af44\dbch\af31505\loch\f44 \hich\f44 icted two paper medication dosage cups labeled \'93\loch\f44 \hich\f44 8 AM\'94\loch\f44 \hich\f44  and \'93\loch\f44 \hich\f44 
8 PM.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 56}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
 The ad conveys an image of a normal, pleasant life achieved through a simple twice-daily medication regimen.  This benign representation of life on OxyContin\'ae\loch\f44  belies the risks inherent in \hich\af44\dbch\af31505\loch\f44 \hich\f44 
this powerful Schedule II narcotic drug.  In keeping with this upbeat imagery, Purdue omitted information on OxyContin\'ae\rquote \loch\f44 \hich\f44 s abuse liability and the other statements contained in the FDA-imposed \'93\loch\f44 \hich\f44 
black box warning\'94\loch\f44  from the body of the ad. 
\par \hich\af44\dbch\af31505\loch\f44 On a January 17, 2\hich\af44\dbch\af31505\loch\f44 003, the FDA sent Purdue a warning letter accusing the company of deceptive advertising.  The letter cited Purdue for the JAMA advertisements and explained: 
\par }\pard \ltrpar\ql \li720\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin720\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \loch\af44\dbch\af31505\hich\f44 \'93\loch\f44 
The typical physician reviewing an advertisement for a prescription drug would expect the most se\hich\af44\dbch\af31505\loch\f44 
rious risks associated with the drug to be included in the body of the ad.  The body of these ads contains no discussion of the potentially fatal risks associated with the drug and its potential for abuse.  Moreover, expectation that the most relevant ris
\hich\af44\dbch\af31505\loch\f44 k\hich\af44\dbch\af31505\loch\f44 s have been disclosed in the body, rather than the brief summary of your ads is exacerbated by having a statement in the body of your ads that begins \hich\f44 \lquote \loch\f44 \hich\f44 
the most serious risk\'85\rquote \loch\f44  implying that what follows is a complete statement of the drug\hich\f44 \rquote \loch\f44 s most serious ri\hich\af44\dbch\af31505\loch\f44 s\hich\af44\dbch\af31505\loch\f44 \hich\f44 
ks, not that there are other, more serious risks to be aware of.  Therefore, the language in the body of your ads reinforces the impression that the most serious risks have been disclosed when in fact they have not. \'85\loch\f44 
the body of these ads contains no disc\hich\af44\dbch\af31505\loch\f44 u\hich\af44\dbch\af31505\loch\f44 \hich\f44 ssion of the potentially fatal risks associated with the drug and its potential for abuse.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 57
\par }\pard \ltrpar\ql \li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 The letter went on to state: 
\par }\pard \ltrpar\ql \li720\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin720\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \loch\af44\dbch\af31505\hich\f44 \'93\loch\f44 \hich\f44 
Your journal advertisements omit and minimize the serious safety risks associated with OxyContin\'ae\loch\f44 , and promote it for uses beyond w\hich\af44\dbch\af31505\loch\f44 \hich\f44 hich have been proven safe and effective\'85\loch\f44 \hich\f44 
your journal advertisements fail to present in the body of the advertisement critical information regarding limitations on the indicated use of OxyContin\'ae\loch\f44 \hich\f44 , thereby promoting OxyContin\'ae\loch\f44  for a much broader range of p
\hich\af44\dbch\af31505\loch\f44 a\hich\af44\dbch\af31505\loch\f44 \hich\f44 tients with pain than are appropriate for the drug.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 57}{\rtlch\fcs1 
\af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44   
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
Subsequently, Purdue published a retraction of its previous false claims and statements in advertisements in the June 18, 2003 issue of the }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 
Journal of the American Medical Association.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 58}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
 Remarkably, \hich\af44\dbch\af31505\loch\f44 \hich\f44 
Purdue, yet again, was able to turn its response to an FDA reprimand into a marketing advantage.  The retraction page contained the black box warning, which was hailed by Purdue in its budget plan as providing an \'93\loch\f44 \hich\f44 
enormous opportunity\'94\loch\f44 \hich\f44  to gain a \'93\loch\f44 competit\hich\af44\dbch\af31505\loch\f44 i\hich\af44\dbch\af31505\loch\f44 \hich\f44 ve advantage\'94\loch\f44  by listing the indication for moderate pain.}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 47}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  Purdue thus used its FDA \'93\loch\f44 \hich\f44 correction\'94
\loch\f44  to again promote its schedule II drug as a substitute for less dangerous, non-addictive drugs.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 47
\par }\pard \ltrpar\ql \li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\insrsid7741077 \hich\af43\dbch\af31505\loch\f43  
\par }{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\ul\insrsid7741077 \hich\af43\dbch\af31505\loch\f43 Purdue\hich\f43 \rquote \loch\f43 s Misrepresentation of Product Features in Marketin\hich\af43\dbch\af31505\loch\f43 g Materials
\par 
\par }{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\insrsid7741077 \hich\af43\dbch\af31505\loch\f43  \tab }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
Purdue has centered its promotional and marketing focus for OxyContin\'ae\loch\f44 \hich\f44  on the q12h dosing schedule. When OxyContin\'ae\loch\f44 \hich\f44  was first introduced, Purdue stated that OxyContin\'ae\loch\f44 \hich\f44  offered a \'93
\loch\f44 \hich\f44 significant advantage\'94\loch\f44  because \hich\f44 \lquote \loch\f44 unlike short-acting pain medic\hich\af44\dbch\af31505\loch\f44 ations, which must be taken every 3 to 6 hours\hich\f44 \emdash \loch\f44 often on an \hich\f44 
\lquote \loch\f44 as needed basis,\hich\f44 \rquote \loch\f44 \hich\f44  OxyContin\'ae\loch\f44 \hich\f44  tablets are taken every 12 hours, providing smooth and sustained pain control all day and all night.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 39}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44   Purdue\hich\f44 \rquote \loch\f44 \hich\f44 s 1998 OxyContin\'ae\loch\f44 
 Budget Plan describes the importance \hich\af44\dbch\af31505\loch\f44 \hich\f44 of q12 dosing to sales, \'93\loch\f44 \hich\f44 Our marketing research indicates that the most important feature of OxyContin\'ae\loch\f44 
 tablets, beyond the familiarity of oxycodone, is the q12h dosing schedule.  In all seven pre-launch market research projects, healthcare professionals \hich\af44\dbch\af31505\loch\f44 s\hich\af44\dbch\af31505\loch\f44 \hich\f44 
tated that this is the most compelling reason to prescribe the OxyContin\'ae\loch\f44 \hich\f44  tablets.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 59
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 However, Purdue\hich\f44 \rquote \loch\f44 
s marketing materials omitted key information on efficacy.  In Purdue\hich\f44 \rquote \loch\f44 \hich\f44 s own pre-launch studies with cancer pain, OxyContin\'ae\loch\f44  did not consistently relieve p\hich\af44\dbch\af31505\loch\f44 \hich\f44 
ain for the entire 12-hour dosing interval.  In its clinical trials, Purdue treated patients who experienced moderate to severe pain while on OxyContin\'ae\loch\f44 \hich\f44  (breakthrough pain) with \'93\loch\f44 \hich\f44 rescue medication\'94
\loch\f44  - short acting oxycodone. In one study, Hagen and Babul r\hich\af44\dbch\af31505\loch\f44 e\hich\af44\dbch\af31505\loch\f44 \hich\f44 ported that, \'93\loch\f44 \hich\f44 
the percentage of rescue analgesic use in the first, second and third 4-hour periods representing the combined 12-hour dosing frequency of controlled release oxycodone\'85\loch\f44 \hich\f44 
 was 23.8%, 42.8% and 33.3% for controlled release oxycodone (OxyContin\'ae.\hich\af44\dbch\af31505\loch\f44 )}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 60}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\cf2\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 Another early trial showed that \'93\loch\f44 \hich\f44 
half of the patients used IR oxycodone rescue (OxyIR) almost daily\'94\loch\f44  revealing that the drug was not able to relieve pain for the full 12 hour dosing schedule.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 61}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  Kaplan et al similarly found that, \'93\loch\f44 Among patients enrolled\hich\af44\dbch\af31505\loch\f44 
\hich\f44 , after the amendment that allowed titration and rescue, 18 of 29 (62%) who received CR oxycodone needed at least one supplemental (rescue) dose\'85\loch\f44 \hich\f44 
 During the day, the median time to first rescue use was 4 hours for the CR (OxyContin\'ae\loch\f44 \hich\f44 ) group.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 62}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44   
\par \hich\af44\dbch\af31505\loch\f44 Purdue was\hich\af44\dbch\af31505\loch\f44 \hich\f44  aware that many OxyContin\'ae\loch\f44  users experienced pain breakthrough after 8 to 10 hours.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 60-62}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
 These patients required q8 dosing.  On the other hand, some patients who have a delayed response may be overmedicated if they are dosed on a q12 basis.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
63}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  Instead of d\hich\af44\dbch\af31505\loch\f44 \hich\f44 
escribing the wide range of patient responses and the importance of individual dose titration, to maintain its marketing \'93\loch\f44 \hich\f44 advantage,\'94\loch\f44  Purdue told physicians that if their patients weren\hich\f44 \rquote \loch\f44 
t experiencing twelve hours of pain relief, they should increase the \hich\af44\dbch\af31505\loch\f44 q\hich\af44\dbch\af31505\loch\f44 12 dose as a response to pain breakthrough.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 61,64}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
  This resulted in  a much higher q12 dose escalation in some patients who instead should have received lower, more frequent dosing.  Purdue also encouraged dose escalation in a marketing piece for doctors ca\hich\af44\dbch\af31505\loch\f44 \hich\f44 
lled, \'93\loch\f44 \hich\f44 Counseling Your Patients and Their Families Regarding the Use of Opioids to Relieve Pain.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 24}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  Purdue instructed doctors on how to answer questions from patients who are hesitant to accept opioid therapy.  One questions stated, \'93\loch\f44 If I develop tolerance
\hich\af44\dbch\af31505\loch\f44  to this drug, what\hich\f44 \rquote \loch\f44 s left for me to take when I }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\ul\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 really}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  need pain relief?\'94\loch\f44 \hich\f44   Purdue suggested that a doctor might reply, \'93\loch\f44 
Tolerance to opioids may occasionally occur.  Usually all it takes to correct this situation is to increase the dose.  Remember, opioid\hich\af44\dbch\af31505\loch\f44 \hich\f44 s are not limited to a \'93\loch\f44 \hich\f44 maximum\'94\loch\f44 
\hich\f44  dose as non-opioids are - an effective dose can be found for virtually any type or severity of pain.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 24}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\insrsid7741077 
\par }\pard \ltrpar\ql \li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
By encouraging ever-higher doses in response to breakthrough pain or increased drug tolerance, Purdue\hich\f44 \rquote \loch\f44 s fixed q12 dosin\hich\af44\dbch\af31505\loch\f44 g recommendations created an addiction generating machine.
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 Purdue\hich\f44 \rquote \loch\f44 
s chief scientist testified that the 12-hour efficacy claim was based on a dream. To win its patents, Purdue told the patent office that OxyContin was unique because 90 percent of patients t\hich\af44\dbch\af31505\loch\f44 
aking the medicine got pain relief by taking very little medicine -- from 10 milligrams to 40 milligrams.
\par \hich\af44\dbch\af31505\loch\f44 But during the 1999 patent trial, Dr. Robert F. Kaiko, OxyContin's inventor, acknowledged that he had done no clinical studies and had no evidence to \hich\af44\dbch\af31505\loch\f44 support this claim.}{\rtlch\fcs1 
\af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 65}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
 Purdue admitted that Dr. Kaiko's ''discovery'' was made solely in his head but that it was valid even though the company was unable to prove it to be true.
\par \hich\af44\dbch\af31505\loch\f44 \hich\f44  As noted above Purdue knew the pain-relieving effect of OxyContin\'ae\loch\f44  was not fixed at 12 hours for all patients. Purdue\hich\f44 \rquote \loch\f44 \hich\f44 s patent stated \'93\loch\f44 
a mean minimum plasma concentration from about 3 to about 30 ng/ml from a}{\rtlch\fcs1 \ab\ai\af46\afs24 \ltrch\fcs0 \b\i\f46\fs24\insrsid7741077 \hich\af46\dbch\af31505\loch\f46  }{\rtlch\fcs1 \ab\ai\af46\afs24 \ltrch\fcs0 
\b\i\f46\fs24\ul\insrsid7741077 \hich\af46\dbch\af31505\loch\f46 mean of about 10 to about 14 hours}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
 after repeated administration every 12 hours through steady-state conditions.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 66}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44  The half-life followed a Gaussian curve with half-lives ranging from 6-14 hours or more (see Figure 1).}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 67
\par }\pard \ltrpar\ql \li0\ri0\nowidctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\par }\pard \ltrpar\ql \li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\par }\pard \ltrpar\qc \li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\insrsid7741077 \hich\af43\dbch\af31505\loch\f43 Figure 1:  Concentration profile of a drug differs among individua
\hich\af43\dbch\af31505\loch\f43 ls
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
This point is further supported by the scientific data that is available on dose ranges.  Sunshine et al determined that the median effective dose interval for OxyContin\'ae\loch\f44  occurred at 10 hours.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 68}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  The OxyContin\'ae\loch\f44  instructions suggest using only a 12-hour d
\hich\af44\dbch\af31505\loch\f44 \hich\f44 osing schedule.  Most other pain medications provide a dosing frequency range to meet variable symptoms and metabolic rates.  Purdue did not use a dose frequency range for OxyContin\'ae\loch\f44 
 for both patent and marketing reasons.  The company understood that its \hich\af44\dbch\af31505\loch\f44 p\hich\af44\dbch\af31505\loch\f44 \hich\f44 atent protection for OxyContin\'ae\loch\f44 \hich\f44 
, and its subsequent success, relied in very large measure on OxyContin\'ae\rquote \loch\f44 s 12 hour duration of effect, so Purdue had huge incentives not to present any other dosing schedule or frequency, and instead focused attention on inc
\hich\af44\dbch\af31505\loch\f44 r\hich\af44\dbch\af31505\loch\f44 easing the dose itself to improve pain relief.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 69  }{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 Changing the dose, however, does not necessarily change a drug\hich\f44 \rquote \loch\f44 \hich\f44 s half-life, so, while an increased dose of OxyContin\'ae\loch\f44 
 may extend the length of time the drug is effective in some people, it does not ensure a\hich\af44\dbch\af31505\loch\f44  full twelve hours of pain relief.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 70}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44   
\par \hich\af44\dbch\af31505\loch\f44 \hich\f44 In its OxyContin\'ae\loch\f44  patent application, Purdue claimed that the dose range from 10 to 40 mg for every 12 hours would control pain in 90% of patients.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 69}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44   However, during a patent infringement case, Purdue failed to provi
\hich\af44\dbch\af31505\loch\f44 de any pre-patent data to support this assertion}{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\cf11\insrsid7741077 ,}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf11\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44  }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 and when Purdue\hich\f44 \rquote \loch\f44 \hich\f44 
s chief scientist on this issue was later asked for evidence to support this claim, he stated that it was based on  blood levels that he \'93\loch\f44 \hich\f44 had in mind,\'94\loch\f44  rather than data.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 69}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  Despite its initia\hich\af44\dbch\af31505\loch\f44 \hich\f44 
l patent claim that 90% of patients would be treated with a maximum 40 mg pill, the available strengths of OxyContin\'ae\loch\f44  reflected Purdue\hich\f44 \rquote \loch\f44 \hich\f44 
s penchant to produce and encourage the use of much higher doses. Purdue introduced OxyContin\'ae\loch\f44  with a maximum strength o\hich\af44\dbch\af31505\loch\f44 f\hich\af44\dbch\af31505\loch\f44 
 40mg, but within a few years, this maximum had escalated four-fold to 160mg, with a full dose range of 10mg to 160mg.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 71}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  (Purdue voluntarily withdrew the 160mg pill in 2001. It retains the right to reintroduce this dose.)}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 72}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  Increasing the dose, if used rep\hich\af44\dbch\af31505\loch\f44 eatedly, increases the risk of tolerance and addiction}{
\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf6\insrsid7741077 .}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
 Nonetheless, Purdue failed to warn physicians or patients of this inherent risk in its drive to increase doses of OxyContin\'ae.
\par \hich\af44\dbch\af31505\loch\f44 Purdue encouraged doctors to double the dose every twelve hours in patient\hich\af44\dbch\af31505\loch\f44 s who had breakthrough pain.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 73}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
 However, the half-life of a drug is a function of the rate of elimination, which increases as the dose increases; higher drug concentrations increase the elimination rate.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 74}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  Thus doubling the dose does not solve the breakthro\hich\af44\dbch\af31505\loch\f44 
ugh problem, but instead increases the likelihood of tolerance development and subsequent symptoms of withdrawal.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 75
\par }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 The increases in pill dosage are further proof of this phenomenon. When released in December 1995, 40 milligrams was the highest dose pill. 
\hich\af44\dbch\af31505\loch\f44 This was based on the representation that doses as high as 80 mg per day would be sufficient to treat >95% of patients.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
69}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  In 1996 the FDA approved a Purdue request to double the maximum pill dosage to 80 mg (160/day).}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 76}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  In 2000 the FDA approved another dou\hich\af44\dbch\af31505\loch\f44 
bling to 160/mg (320/day).}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 77}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
 The maximum available dose thus increased four-fold in four years. As noted above, these increases resulted from the fact that Oxycontin\'ae\loch\f44  pain relief did not last 12 hours for most patients. Increasing the q12 dose increased op
\hich\af44\dbch\af31505\loch\f44 ioid tolerance and caused subsequent withdrawal symptoms if the dose was reduced, creating a vicious cycle promoting addiction while enhancing profits.
\par }\pard \ltrpar\ql \li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\ul\insrsid7741077 
\par \hich\af43\dbch\af31505\loch\f43 Downplaying Addiction
\par }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
Additionally, Purdue downplayed the addiction potential of OxyContin\'ae\loch\f44  by claimin\hich\af44\dbch\af31505\loch\f44 \hich\f44 g that, "delayed absorption is believed to reduce the abuse liability of a drug.\'94}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 26}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
 The label made this claim for almost five years, from December 5, 1995 and November 27, 2000. In the OxyContin\'ae\loch\f44  product brochure and in sales representative training materi\hich\af44\dbch\af31505\loch\f44 \hich\f44 
als, this same assertion was expressed as "delayed absorption, as provided by OxyContin\'ae\loch\f44 \hich\f44  Tablets, is believed to reduce the attraction of a drug for abuse.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 78}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  Purdue has never tested this claim. A search of Medline failed to reveal any study that supported
\hich\af44\dbch\af31505\loch\f44  the claim that controlled-release opioids are any less likely to lead to addiction than immediate release opioids.  Purdue\hich\f44 \rquote \loch\f44 
s claim appears to be premised on the assumption that drug abusers seeking an immediate high would not prefer a drug with a slower \hich\af44\dbch\af31505\loch\f44 r\hich\af44\dbch\af31505\loch\f44 \hich\f44 
elease. However, the higher doses of the active drug in OxyContin\'ae\loch\f44 \hich\f44  tablets increased their attractiveness for addicts. This view is supported by the \'93\loch\f44 \hich\f44 street value\'94\loch\f44 \hich\f44  of OxyContin\'ae
\loch\f44  tablets, currently going for about a dollar per milligram, clearly revealing \hich\af44\dbch\af31505\loch\f44 t\hich\af44\dbch\af31505\loch\f44 \hich\f44 hat the higher dose tablets are much sought after, despite their \'93\loch\f44 \hich\f44 
controlled release.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 79}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
 Also, opioid addicts suffer debilitating physical and emotional symptoms when they go into withdrawal.  They take what they can get, whether it is a controlled or imme\hich\af44\dbch\af31505\loch\f44 
diate release drug, to relieve these symptoms. As should have been expected}{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\insrsid7741077 ,}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
 addicts quickly learned to circumvent the \'93\loch\f44 \hich\f44 slow absorption\'94\loch\f44  by crushing and chewing the pills.  Ironically Purdue\hich\f44 \rquote \hich\af44\dbch\af31505\loch\f44 
s previous long acting opioid, MS Contin could not be misused this way.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 80}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf19\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44  }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 Purdue\hich\f44 \rquote \loch\f44 \hich\f44 s presumption that OxyContin\'ae\loch\f44 \hich\f44 
 is like other, less potent, controlled-release drugs, and is less attractive to opioid addicts is contradicted by the epidemic of OxyContin\'ae\loch\f44  abus\hich\af44\dbch\af31505\loch\f44 e.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 1
\par }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 Moreover, Purdue reported that its OxyContin\'ae\loch\f44 
 formulation had a biphasic release, including a rapid onset analgesic phase in addition to its long-acting phase.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 34}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  Even if \'93\loch\f44 \hich\f44 slow-onset\'94\loch\f44  reduces the risk of addiction, Purdue\hich\f44 \rquote \loch\f44 \hich\f44 s \'93\loch\f44 \hich\f44 biphasic\'94
\loch\f44 \hich\f44  OxyContin\'ae\loch\f44  formula\hich\af44\dbch\af31505\loch\f44 tion did not provide this protection.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 81}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  If the speed of absorption affects the addiction potential, then OxyContin\'ae\rquote \loch\f44 s fast release component would presumably }{\rtlch\fcs1 \ai\af45\afs24 
\ltrch\fcs0 \i\f45\fs24\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 increase}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
 the risk of addiction. Furthermore, if this claim is accurate, Purdue not only provides a\hich\af44\dbch\af31505\loch\f44 \hich\f44  claimed "slow release" oxycodone (OxyContin\'ae\loch\f44 \hich\f44 
), but also markets "rapid release" OxyIR and OxyFast which are often used off label as breakthrough medication in conjunction with OxyContin\'ae.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 82,61}{
\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  If OxyContin\'ae\loch\f44  had a lowered addiction risk because of its cont\hich\af44\dbch\af31505\loch\f44 
rolled release, then these fast-acting opioids present a}{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf6\insrsid7741077 \hich\af45\dbch\af31505\loch\f45  }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\insrsid7741077 
\hich\af45\dbch\af31505\loch\f45 higher}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  addiction potential. Purdue, however, issued no warnings regarding elevated addiction risk for OxyIR or OxyFAST. 

\par }\pard \ltrpar\ql \li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\par }{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\ul\insrsid7741077 \hich\af43\dbch\af31505\loch\f43 Grapefruit and Alcohol Drug Interactions \hich\f43 \endash \loch\f43  the Greyhound to death
\par }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  Ingestion\hich\af44\dbch\af31505\loch\f44 \hich\f44 
 of grapefruit juice can \'93\loch\f44 \hich\f44 increase plasma concentrations and clinical effects of oxycodone\'94.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 83}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\cf19\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
Consumption of grapefruit juice can lead to increased side effects from OxyCodone, such as nausea, itch, and dizziness. Being that grapefruit juice inhibits the \hich\af44\dbch\af31505\loch\f44 \hich\f44 enzyme which mediates the \'93\loch\f44 \hich\f44 
first-pass metabolism of oxycodone\'94\loch\f44 , when paired with the drug grapefruit increases the concentration and the clinical effects.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 83}{
\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  When oxycodone is mixed with alcohol, the short-term effects on the body can be extremely damaging \hich\af44\dbch\af31505\loch\f44 
and dangerous. The exposure of extended-release oxycodone in the body is increased heavily when administered with ethanol.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 84}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  
\par }\pard \ltrpar\ql \li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \tab \hich\af44\dbch\af31505\loch\f44 Purdue\hich\f44 \rquote \loch\f44 
s warning label fails to acknowledge the dangers of both alcohol and grapefruit juice when used in conjunction with the dr\hich\af44\dbch\af31505\loch\f44 
ug. The warning label, last revised in 2015, only cites possible drug interactions of oxycodone with CNS depressants and mixed agonist drugs.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 73}{
\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  Yet in the entire thirty-nine-page long warning packet, Purdue fails to caution patients against ingesting alcoh\hich\af44\dbch\af31505\loch\f44 \hich\f44 
ol when they have been prescribed OxyContin\'ae\loch\f44 
. Lack of warning puts patients at-risk for using OxyContin along with alcohol or brain depressant drugs or medications without being aware of the possible harm to critical life-sustaining functions.
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 The greyhoun\hich\af44\dbch\af31505\loch\f44 
d is a popular alcoholic drink that is a mixture of grapefruit juice and either gin or vodka. Malhotra et al. found that 80 proof drinks, similar to the greyhound, which are made up of forty percent ethanol increased the maximum concentration of oxycodone
\hich\af44\dbch\af31505\loch\f44  \hich\af44\dbch\af31505\loch\f44 by thirty-seven percent.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 85}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  This increase in concentration means that first time users of oxycodone are particularly susceptible to increased concentrations of the drug when they ingest hard alcohol alongside it.}{
\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 85}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44   Teenagers at parties may often be unaware
\hich\af44\dbch\af31505\loch\f44  of the effect that oxycodone can have on their system when combined with alcohol. An example of this phenomenon occurred in 2016.  Jack Granger and his 19-year old brother, Nick, died after hosting a party.}{\rtlch\fcs1 
\af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 86}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  Toxicology results indicated that they died fr
\hich\af44\dbch\af31505\loch\f44 om a combination of oxycodone and alcohol.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 87}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44  
\par }\pard \ltrpar\ql \li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\ul\insrsid7741077 
\par \hich\af43\dbch\af31505\loch\f43 How OxyContin Co-opted and Subverted the FDA Regulatory Process
\par 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
This review has highlighted the marketing strategy of a drug manufacturer that had drawn multiple citations and warnings from the FDA.  Purdue exploited the FDA\hich\f44 \rquote \loch\f44 
s citations, none of which was accompanied by fines, by using them to further marketing object\hich\af44\dbch\af31505\loch\f44 i\hich\af44\dbch\af31505\loch\f44 \hich\f44 ves and mislead health practitioners about the addictive potential of Oxycontin\'ae
\loch\f44 \hich\f44 . After FDA intervention, Purdue continued to omit important information from the OxyContin\'ae\loch\f44  label, and continued to distribute marketing materials that misrepresented the pur\hich\af44\dbch\af31505\loch\f44 p
\hich\af44\dbch\af31505\loch\f44 \hich\f44 orted benefits and greatly minimized the  risks of the drug.  Properly informed physicians and educated consumers are the best protections against the inherent risks of abuse, addiction and death from OxyContin
\'ae\loch\f44 .  The FDA, which is supposed to protect the\hich\af44\dbch\af31505\loch\f44  \hich\af44\dbch\af31505\loch\f44 
public and to assure that accurate information is available for prescribers, repeatedly failed to fulfil its mission in the case of OxyContin. The OxyContin story reveals that the FDA can be captured by the industry it is supposed to regulate. The OxyCont
\hich\af44\dbch\af31505\loch\f44 i\hich\af44\dbch\af31505\loch\f44 \hich\f44 n\'ae\loch\f44 
 chronicle indicates the many and varied ways in which a pharmaceutical manufacturer can undermine and compromise the regulatory process to the detriment of consumer safety.  It also reveals some of the inadequacies of the FDA monitoring and regulatory 
\hich\af44\dbch\af31505\loch\f44 a\hich\af44\dbch\af31505\loch\f44 \hich\f44 pparatus. Many economists have noted that over time, regulatory agencies become \'93\loch\f44 \hich\f44 captured\'94\loch\f44  by the industries they regulate.}{\rtlch\fcs1 
\af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 88}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  The OxyContin\'ae\loch\f44 
 case demonstrates that the FDA must constantly be held accountable for the possibility that its authority is compro\hich\af44\dbch\af31505\loch\f44 \hich\f44 
mised by pharmaceutical manufacturers in their quest for greater sales and profits. The revolving door marketing strategy that encourages pharmaceutical companies to hire FDA regulators was clearly exploited in the case of OxyContin\'ae\loch\f44 
 and must be prohibite\hich\af44\dbch\af31505\loch\f44 d\hich\af44\dbch\af31505\loch\f44 .  
\par \hich\af44\dbch\af31505\loch\f44 \hich\f44 But the problem is far larger. As Janis noted, collective decision making is often accompanied by \'93\loch\f44 \hich\f44 Groupthink\'94\loch\f44 \hich\f44 : a process that encourages a \'93}{\rtlch\fcs1 
\ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 go}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44  along to get along\'94\loch\f44  attitude.}{\rtlch\fcs1 
\af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 89}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
 The FDA regulator is a part of the group along with the pharmaceutical compa\hich\af44\dbch\af31505\loch\f44 \hich\f44 ny employees. They meet with each other on a regular basis and have regular phone contact and it is only natural \'93\loch\f44 
\hich\f44 to want to get along.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 89}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 
 No one wants to be in adversarial relationship over time. It is only natural for a \'93\loch\f44 \hich\f44 give and take relationship\'94\loch\f44  to de\hich\af44\dbch\af31505\loch\f44 \hich\f44 
velop. Janis recommended organizational changes in decision-making that would reduce or eliminate errors related to \'93\loch\f44 \hich\f44 Groupthink.\'94}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44 89}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
 Therefore we propose that the FDA establish a patient advocate division separate and independent of the drug approval divisi\hich\af44\dbch\af31505\loch\f44 \hich\f44 
on. Each drug would be assigned a patient advocate who would attend all meetings, monitor phone calls and other interactions with the drug sponsor. They would serve as a Janis \'93\loch\f44 devil\hich\f44 \rquote \loch\f44 \hich\f44 s advocate.\'94
\loch\f44  
\par }\pard \ltrpar\ql \li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\par }{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\ul\insrsid7741077 \hich\af43\dbch\af31505\loch\f43 Conclusion
\par }{\rtlch\fcs1 \ab\af43\afs24 \ltrch\fcs0 \b\f43\fs24\insrsid7741077 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa120\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 \hich\f44 The OxyContin\'ae\loch\f44  case raises important questions
\hich\af44\dbch\af31505\loch\f44 \hich\f44 
 of industry accountability and responsibility in the production, marketing and sale of potentially dangerous drugs and narcotics. Proper, appropriate, balanced, complete, and scientifically valid information must be in the hands of physician \'93
\loch\f44 learned int\hich\af44\dbch\af31505\loch\f44 e\hich\af44\dbch\af31505\loch\f44 \hich\f44 rmediaries.\'94\loch\f44 
 As we noted, direct to consumer marketing can circumvent physician judgment and cautious risk-avoidance in medication prescribing. Purdue Pharma, in its relentless zeal for sales growth and profits, abdicated its responsibility by subverting 
\hich\af44\dbch\af31505\loch\f44 g\hich\af44\dbch\af31505\loch\f44 \hich\f44 
overnmental regulatory authority, and by repeatedly and systematically misinforming prescribing doctors and the public about the characteristics and inherent risks of its Schedule II narcotic, OxyContin\'ae\loch\f44 
. This case demonstrates that physicians who prescri\hich\af44\dbch\af31505\loch\f44 b\hich\af44\dbch\af31505\loch\f44 \hich\f44 
e narcotics for pain need to be vigilant for self-serving, invalid, or unbalanced claims in their review of advertisements and corporate sales promotions for drugs, especially those, like OxyContin\'ae\loch\f44 
, with potential for abuse, diversion, addiction, overdos\hich\af44\dbch\af31505\loch\f44 e\hich\af44\dbch\af31505\loch\f44  and death. 
\par \hich\af44\dbch\af31505\loch\f44 Companies are not self-regulating.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\super\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 90}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\hich\af44\dbch\af31505\loch\f44  They have an obligation to stockholders to maximize profits by increasing revenues and by minimizing or avoiding costs, including social costs and the costs of adverse reactions to their products. Physician
\hich\af44\dbch\af31505\loch\f44 
s need to be aware that these business imperatives can drive marketing practices which are not scientifically or ethically based and which may be based on flawed or untested clinical assumptions. This case demonstrates the continued need for caution and c
\hich\af44\dbch\af31505\loch\f44 a\hich\af44\dbch\af31505\loch\f44 re in considering corporate pharmaceutical advice, especially when considering the prescribing of narcotic analgesics for non-malignant pain. 
\par }\pard \ltrpar\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\par }\pard \ltrpar\qc \li0\ri0\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\insrsid7741077 
\par 
\par 
\par 
\par 
\par 
\par 
\par \page 
\par }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 Reference List
\par }\pard \ltrpar\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 
\par \hich\af44\dbch\af31505\loch\f44 1. \~\~\hich\f44 United States Drug Enforcement Administration. OxyContin\'ae\loch\f44 : Pharmaceutical Diversio\hich\af44\dbch\af31505\loch\f44 n. \~
2002. Retrieved from https://www.deadiversion.usdoj.gov/pubs/presentations/euus2013.pdf
\par \hich\af44\dbch\af31505\loch\f44 2. Van Zee A. (2009). The promotion and marketing of oxycontin: commercial triumph, public health tragedy. }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 
American journal of public health}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 , 99(2), 221-7. 
\par \hich\af44\dbch\af31505\loch\f44 3. What Are The Dangers of Snorting or Injecting OxyContin?. (2019). Retrieved from https://americanaddictioncenters.org/prescription-drugs/smoking-snorting-injecting 
\par \hich\af44\dbch\af31505\loch\f44 4. Meier, B. (2018). Origins of an Epidemic: Purdue Pharma Knew Its Opiods Were Widely A\hich\af44\dbch\af31505\loch\f44 bused. }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 
\hich\af45\dbch\af31505\loch\f45 New York Times}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 . https://www.nytimes.com/2018/05/29/health/purdue-opioids-oxycontin.html
\par \hich\af44\dbch\af31505\loch\f44 5. Meier, B. (2003). Pain Killer. Emmaus, Pa.: Rodale.
\par \hich\af44\dbch\af31505\loch\f44 6. Alam, A., & Juurlink, D. N. (2016). The prescription opioid epidemic: an overview for anesthesiologists\hich\af44\dbch\af31505\loch\f44 . }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 
\hich\af45\dbch\af31505\loch\f45 Canadian Journal of Anesthesia/Journal Canadien d\hich\f45 \rquote \loch\f45 \hich\f45 anesth\'e9\loch\f45 sie}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 , }{
\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 63}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 (1), 61\hich\f44 \endash \loch\f44 
68. https://doi.org/10.1007/s12630-015-0520-y
\par \hich\af44\dbch\af31505\loch\f44 7. Jones, M. R., Viswanath, O., Peck, J., Kaye, A. D., Gill, J. S., & Simopoulos, T. T. (2018). A Brief History of the Opioid Epidemic a\hich\af44\dbch\af31505\loch\f44 nd Strategies for Pain Medicine. }{\rtlch\fcs1 
\ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 Pain and Therapy}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 , }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 
\i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 7}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 (1), 13\hich\f44 \endash \loch\f44 21. https://doi.org/10.1007/s40122-018-0097-6
\par \hich\af44\dbch\af31505\loch\f44 8. Purdue Pharma. I Got My Life Back. Marketing Brochure. \~1997. Norwalk, CT, Purdue Pharma. https://repository.library.brown.edu/studio/item/bdr:8417\hich\af44\dbch\af31505\loch\f44 55/
\par \hich\af44\dbch\af31505\loch\f44 \hich\f44 9.\'93\loch\f44 \hich\f44 News & Media.\'94\loch\f44  }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 
Pharmaceutical & Healthcare News from Purdue Pharma L.P., }{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 www.purduepharma.com/news-media/common-myths-about-OxyContin/.
\par \hich\af44\dbch\af31505\loch\f44 \hich\f44 10. Medina, Jose L., and Seymour Diamond. \'93\loch\f44 \hich\f44 Drug Dependency in Patients with Chronic Headaches.\'94\loch\f44  }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 
\hich\af45\dbch\af31505\loch\f45 Headache: The Jou\hich\af45\dbch\af31505\loch\f45 rnal of Head and Face Pain}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 , vol. 17, no. 1, 1977, pp. 12\hich\f44 
\endash \loch\f44 14., doi:10.1111/j.1526-4610.1977.hed1701012.x.
\par \~\hich\af44\dbch\af31505\loch\f44 11. \~\~Perry, S., & Heidrich, G. (1982). Management of pain during debridement: A survey of U.S. burn units. }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 Pain,
}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 13}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 (3), 267-280. doi:10.1016/0304-395\hich\af44\dbch\af31505\loch\f44 9(82)90016-1
\par \~\hich\af44\dbch\af31505\loch\f44 12. \~\~\hich\f44 Porter, J, and Jick H. \'93\loch\f44 \hich\f44 Addiction Rare in Patients Treated with Narcotics.\'94\loch\f44  }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 
\hich\af45\dbch\af31505\loch\f45 New England Journal of Medicine}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 , vol. 302, no. 2, ser. 123, 10 Jan. 1980
\par \hich\af44\dbch\af31505\loch\f44 13. \~\~American Psychiatric Association. }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 Diagnostic and Statistical Manual of Mental Dis
\hich\af45\dbch\af31505\loch\f45 orders}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
. 2nd ed. Washington, D.C.: American Psychiatric Association; 1968. https://www.madinamerica.com/wp-content/uploads/2015/08/DSM-II.pdf
\par \hich\af44\dbch\af31505\loch\f44 14. \~\~\hich\f44 Meier, Barry. \'93\loch\f44 \hich\f44 The Delicate Balance of Pain and Addiction.\'94\loch\f44  }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 
New York Times}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 , 25 Nov 2003, www.nytimes.com/2003\hich\af44\dbch\af31505\loch\f44 /11/25/science/the-delicate-balance-of-pain-and-addiction.html
\par \hich\af44\dbch\af31505\loch\f44 15. \~\~Jick, Hershel. Deposition. \~34, 19-20. 9-19-2002. https://repository.library.brown.edu/studio/item/bdr:841737/
\par \hich\af44\dbch\af31505\loch\f44 16. \~\~}{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 Mental Disorders: Diagnostic and Statistical Manual}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 . First ed. Washing\hich\af44\dbch\af31505\loch\f44 ton, DC: The American Psychiatric Association Committee on Nomenclature and Statistics; 1952.
\par \hich\af44\dbch\af31505\loch\f44 17. \~\~\hich\f44 Fishbain, David A., et al. \'93\loch\f44 \hich\f44 Drug Abuse, Dependence, and Addiction in Chronic Pain Patients.\'94\loch\f44  }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 
\hich\af45\dbch\af31505\loch\f45 The Clinical Journal of Pain}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 , vol. 8, no. 2, 1992, pp. 77\hich\f44 \endash \loch\f44 85., 
\hich\af44\dbch\af31505\loch\f44 doi:10.1097/00002508-199206000-00003.
\par \hich\af44\dbch\af31505\loch\f44 18. \~\~\hich\f44 Dickinson, B. D. \'93\loch\f44 \hich\f44 Use of Opioids to Treat Chronic, Noncancer Pain.\'94\loch\f44  }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 
\hich\af45\dbch\af31505\loch\f45 Western Journal of Medicine}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 , vol. 172, no. 2, Jan. 2000, pp. 107\hich\f44 \endash \loch\f44 
115., doi:10.1136/ewjm.172.2.107.
\par \hich\af44\dbch\af31505\loch\f44 19. \~\~\hich\f44 Kouyanou, Kyriaki, et al. \'93\loch\f44 Medication M\hich\af44\dbch\af31505\loch\f44 \hich\f44 isuse, Abuse and Dependence in Chronic Pain Patients.\'94\loch\f44  }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 
\i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 Journal of Psychosomatic Research}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 , vol. 43, no. 5, 1997, pp. 497\hich\f44 \endash 
\loch\f44 504., doi:10.1016/s0022-3999(97)00171-2.
\par \hich\af44\dbch\af31505\loch\f44 20. \~\~\hich\f44 Hoffmann, Norman G., et al. \'93\loch\f44 Prevalence of Abuse and Dependency in Chronic Pain Patients.\loch\af44\dbch\af31505\hich\f44 \'94\loch\f44  }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 
\i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 International Journal of the Addictions}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 , vol. 30, no. 8, 1995, pp. 919\hich\f44 \endash 
\loch\f44 927., doi:10.3109/10826089509055820.
\par \hich\af44\dbch\af31505\loch\f44 21. \~\~\hich\f44 Ballantyne, Jane C. \'93\loch\f44 \hich\f44 Assessing the Prevalence of Opioid Misuse, Abuse, and Addiction in Chronic Pain.\'94\loch\f44  }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 
\i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 Pain}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 , vol. 156, no. 4, 2015, pp. 567\hich\f44 \endash \hich\af44\dbch\af31505\loch\f44 
568., doi:10.1097/j.pain.0000000000000105.
\par \hich\af44\dbch\af31505\loch\f44 22. \~\~\hich\f44 Maruta, T, et al. \'93\loch\f44 \hich\f44 Drug Abuse and Dependency in Patients with Chronic Pain.\'94\loch\f44  }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 
\hich\af45\dbch\af31505\loch\f45 Mayo Clinic Proceedings}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 , vol. 54, no. 4, Apr. 1979, pp. 241\hich\f44 \endash \loch\f44 244.
\par \hich\af44\dbch\af31505\loch\f44 23. \~\~\hich\f44 Maruta, Tosumiko, and David W. Swanson. \'93\loch\f44 Problems with the \hich\af44\dbch\af31505\loch\f44 \hich\f44 Use of Oxycodone Compound in Patients with Chronic Pain.\'94\loch\f44  }{\rtlch\fcs1 
\ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 Pain}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 , vol. 11, no. 3, 1981, pp. 389\hich\f44 \endash \loch\f44 
396., doi:10.1016/0304-3959(81)90638-2.
\par \hich\af44\dbch\af31505\loch\f44 24. \~\~Purdue Pharma. Counseling Your Patients and Their Families Regarding the Use of Opioids to \~Relieve Pain. Partners A\hich\af44\dbch\af31505\loch\f44 
gainst Pain. 1997. Norwalk, CT, Purdue Pharma. https://repository.library.brown.edu/studio/item/bdr:841753/
\par \hich\af44\dbch\af31505\loch\f44 25. \~\~Purdue Pharma. From One Pain Patient to Another. Purdue Pharma Promotional Video and Pamphlet. \~2000. Norwalk, CT, Purdue Pharma. https://repo\hich\af44\dbch\af31505\loch\f44 
sitory.library.brown.edu/studio/item/bdr:841752/
\par \hich\af44\dbch\af31505\loch\f44 26. \~\~\hich\f44 Physicians' Desk Reference. OxyContin\'ae\loch\f44  Package Insert. 51st, 2166. 1997. Montvale, NJ, Thompson PDR.
\par \hich\af44\dbch\af31505\loch\f44 27. \~\~\hich\f44 Physicians' Desk Reference. OxyContin\'ae\loch\f44  Package Insert. 57th, 2852-2853. 2003. Montvale, NJ, Th\hich\af44\dbch\af31505\loch\f44 ompson PDR.
\par \hich\af44\dbch\af31505\loch\f44 28. \~\~\hich\f44 Food and Drug Administration. FDA Talk Paper: FDA Strengthens Warnings for OxyContin\'ae\loch\f44 . \~7-25-2001.
\par \hich\af44\dbch\af31505\loch\f44 29. \~\~Wright, Curtis. Deposition. \~88-94. 7-25-2003.
\par \hich\af44\dbch\af31505\loch\f44 30. \~\~The Agency for Healthcare Research and Quality. Acute Pain Management: Operative\hich\af44\dbch\af31505\loch\f44  or Medical Procedures and Trauma Clinical Practice Guideline No. 1. AHCPR Publication No. 92-0032. 
\~1992.
\par \hich\af44\dbch\af31505\loch\f44 31. \~\~\hich\f44 Physicians' Desk Reference. OxyContin\'ae\hich\af44\dbch\af31505\loch\f44  Package Insert. 52nd. 1998. Montvale, NJ, Thompson PDR.
\par \hich\af44\dbch\af31505\loch\f44 32. \~\~\hich\f44 Physicians' Desk Reference. OxyContin\'ae\loch\f44  Package Insert. 53rd. 1999. Montvale, NJ, Thompson PDR.
\par \hich\af44\dbch\af31505\loch\f44 33. \~\~\hich\f44 Physicians' Desk Reference. OxyContin\'ae\loch\f44  Package Insert. 54th, 2539. 2000. Montvale, NJ, Thomp\hich\af44\dbch\af31505\loch\f44 son PDR.
\par \hich\af44\dbch\af31505\loch\f44 34. \~\~\hich\f44 Physicians' Desk Reference. OxyContin\'ae\loch\f44  Package Insert. 55th. 2001. Montvale, NJ, Thompson PDR.
\par \hich\af44\dbch\af31505\loch\f44 35. \~\~Physicians' Desk Reference. MS Contin Package Insert. 51st, 2150. 1997. Montvale, NJ, Thompson PDR.
\par \hich\af44\dbch\af31505\loch\f44 36. \~\~Physicians' Desk Reference. OraMor\hich\af44\dbch\af31505\loch\f44 ph Package Insert. 51st, 2360. 1997. Montvale, NJ, Thompson PDR.
\par \hich\af44\dbch\af31505\loch\f44 37. \~Purdue Pharma. Global Network. Retrieved from https://www.purduepharma.com/partnering-with-purdue/pharma-capabilities/global-network/
\par \hich\af44\dbch\af31505\loch\f44 38. \~\~Austria-Codex Fachinformation. \~\hich\f44 2004. Wien, \'d6\loch\f44 s\hich\af44\dbch\af31505\loch\f44 terreichischer Apotheker. https://repository.library.brown.edu/studio/item/bdr:841750/
\par \hich\af44\dbch\af31505\loch\f44 39. \~\~\hich\f44 Purdue Pharma. New Hope for Millions of Americans Suffering from Persistent Pain: Long-Acting OxyContin\'ae\loch\f44  Tablets Now Available to Relieve Pain. PR Newswire . 5-31-
\hich\af44\dbch\af31505\loch\f44 1996.
\par \hich\af44\dbch\af31505\loch\f44 40. \~\~Purdue Pharma. Proven Effective in Arthritis Pain. New England Journal of Medicine . 5-4-2000. https://repository.library.brown.edu/studio/item/bdr:841754/
\par \hich\af44\dbch\af31505\loch\f44 41. \~\~Salis, S. FDA Warning Letter. \~5-11-2000. https://repository.library.brown.edu/stu\hich\af44\dbch\af31505\loch\f44 dio/item/bdr:841751/
\par \hich\af44\dbch\af31505\loch\f44 42. \~\~\hich\f44 Purdue Pharma. 2001 Budget Plan: OxyContin\'ae\loch\f44  Tablets. \~
4-51. 2001. https://www.documentcloud.org/documents/4490150-OxyContin2001.html?embed=true&pdf=true&responsive=false&sidebar=false&text=true
\par \hich\af44\dbch\af31505\loch\f44 43. Meier, B. (2002). OxyContin Dea\hich\af44\dbch\af31505\loch\f44 ths May Top Early Count. Retrieved from https://www.nytimes.com/2002/04/15/us/oxycontin-deaths-may-top-early-count.html
\par \hich\af44\dbch\af31505\loch\f44 44. \~\~\hich\f44 Physicians' Desk Reference. OxyContin\'ae\loch\f44  Package Insert. 56th, 2914. 2002. Montvale, NJ, Thompson PDR.
\par \hich\af44\dbch\af31505\loch\f44 45. \~\~}{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 Diagnostic and Statisti\hich\af45\dbch\af31505\loch\f45 cal Manual of Mental Disorders, Fourth Edition}{
\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 . 4 ed. Washington DC: The American Psychiatric Association Committee on Nomenclature and Statistics; 1994.
\par \hich\af44\dbch\af31505\loch\f44 46. \~\~Weissman DE, Haddox JD. Opioid pseudoaddiction--an iatrogenic syndrome. }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 Pain.}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  1989;36:363-366.
\par \hich\af44\dbch\af31505\loch\f44 4\hich\af44\dbch\af31505\loch\f44 7. \~\~\hich\f44 Purdue Pharma. 2002 Budget Plan: OxyContin\'ae\loch\f44  Tablets. \~
1-47. 2002. Purdue Pharma. https://www.documentcloud.org/documents/4490164-OxyContin2002.html?embed=true&pdf=true&responsive=false&sidebar=false&text=true
\par \hich\af44\dbch\af31505\loch\f44 48. \~\~Purdue Pharma. A Guide to Your New P\hich\af44\dbch\af31505\loch\f44 ain Medication and How to Become a Partner Against Pain. https://repository.library.brown.edu/studio/item/bdr:841749/
\par \hich\af44\dbch\af31505\loch\f44 49. \~\~Purdue Pharma. How you can be a Partner Against Pain and Gain Control over your own Pain. \~2001. https://repository.library.brown.ed\hich\af44\dbch\af31505\loch\f44 u/studio/item/bdr:841738/
\par \hich\af44\dbch\af31505\loch\f44 50. \~\~World Health Organization. Cancer Pain Relief. \~1986. Geneva, Switzerland, World Health Organization. https://apps.who.int/iris/handle/10665/37896
\par \hich\af44\dbch\af31505\loch\f44 51. \~\~\hich\f44 United States General Accounting Office. Prescription Drugs: OxyContin\'ae\hich\af44\dbch\af31505\loch\f44  Abuse and Diversion and Efforts to Address the Problem. \~
2003. https://www.gao.gov/htext/d04110.html
\par \hich\af44\dbch\af31505\loch\f44 52. \~\~Purdue Pharma. Promotional Letter. \~1-8-1998. https://repository.library.brown.edu/studio/item/bdr:841748/
\par \hich\af44\dbch\af31505\loch\f44 53. \~\~Testimony of David Haddox on behalf\hich\af44\dbch\af31505\loch\f44  of Purdue Pharma before the Subcommitte on Criminal Justice, Drug Policy, and Human Resources of the Committee on Government Reform. \~
Exhibit B-3. 2-9-2004. https://repository.library.brown.edu/studio/item/bdr:841747/
\par \hich\af44\dbch\af31505\loch\f44 54. \~\~Purdue Pharma. 1997 Budget Plan\hich\af44\dbch\af31505\loch\f44 \hich\f44 : OxyContin\'ae\loch\f44  Tablets. \~
2-36-2-26. 1997. https://www.documentcloud.org/documents/4490123-OxyContin1997.html?embed=true&pdf=true&responsive=false&sidebar=false&text=true
\par \hich\af44\dbch\af31505\loch\f44 55. \~\~Purdue Pharma. Effective Relief Takes Just Two. JAMA: The Journal of the American \hich\af44\dbch\af31505\loch\f44 Medical Association . 10-2-2002. https://repository.library.brown.edu/studio/item/bdr:841754/

\par \hich\af44\dbch\af31505\loch\f44 56. \~\~Purdue Pharma. There Can Be Life With Relief. JAMA: The Journal of the American Medical Association . 11-13-2002. https://repository.library.brown.edu/studi\hich\af44\dbch\af31505\loch\f44 o/item/bdr:841753/
\par \hich\af44\dbch\af31505\loch\f44 57. \~\~Abrams, T. \~FDA Warning Letter. to Friedman, M. \~1-17-2003. https://repository.library.brown.edu/studio/item/bdr:841746/
\par \hich\af44\dbch\af31505\loch\f44 58. \~\~Reder, R. Important Correction: Letter to Health Care Practitioners. JAMA: The Journal of the American M\hich\af44\dbch\af31505\loch\f44 edical Association . 7-18-2003.
\par \hich\af44\dbch\af31505\loch\f44 59. \~\~Purdue Pharma. 1998 Budget Plan. \~\hich\af44\dbch\af31505\loch\f44 
4-41. 1998. Purdue Pharma. https://www.documentcloud.org/documents/4490129-OxyContin1998.html?embed=true&pdf=true&responsive=false&sidebar=false&text=true
\par \hich\af44\dbch\af31505\loch\f44 60. \~\~Hagen NA, Babul N. Comparative Clinical Efficacy and Safety of a Novel Controlled-Release Oxyco\hich\af44\dbch\af31505\loch\f44 
done Formulation and Controlled-Release Hydromorphone in the Treatment of Cancer Pain. }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 Cancer.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 
\f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  1997;1:1492.
\par \hich\af44\dbch\af31505\loch\f44 61. \~\~Citron M, Kaplan R, Parris W, et al. Long-Term Administration of Controlled-Release Oxycodone Tablets for the Treatment of Cancer Pain. }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 
\hich\af45\dbch\af31505\loch\f45 Cancer\hich\af45\dbch\af31505\loch\f45  Investigation.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  1998;8:563.
\par \hich\af44\dbch\af31505\loch\f44 62. \~\~Kaplan R, Parris WC, Citron ML, et al. Comparison of Controlled-Release and Immediate-Release Oxycodone Tablets in Patients with Cancer Pain. }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 
\hich\af45\dbch\af31505\loch\f45 J Clin Oncol.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  1998;16:3232-3233.
\par \hich\af44\dbch\af31505\loch\f44 63. \~\~Blumenthal, R and (Attorney General State\hich\af44\dbch\af31505\loch\f44 \hich\f44  of Connecticut). Petition to Require Purdue Pharma LP to Revise the Labeling of OxyContin\'ae\loch\f44 
 Tablets to Strengthen Warnings of the Greater Potential for Developing Side \~Effects and Adverse Drug Reactions Due to Prescribing Dosing Frequencies in Excess of \hich\af44\dbch\af31505\loch\f44 t\hich\af44\dbch\af31505\loch\f44 
he Recommended Guidelines. 1-23-2004.
\par \hich\af44\dbch\af31505\loch\f44 64. \~\~Purdue Pharma. Professional Sales Aid, Artwork No. C5180. \~5-25-1999. https://repository.library.brown.edu/studio/item/bdr:841742/
\par \hich\af44\dbch\af31505\loch\f44 65. Kaiko, Robert. Deposition. 10-22-1999. https://repository.library.brown.edu/s\hich\af44\dbch\af31505\loch\f44 tudio/item/bdr:841736/
\par \hich\af44\dbch\af31505\loch\f44 66. Patent held by Purdue Pharma. Number US20100092570A1. Retrieved from https://patents.google.com/patent/US20100092570A1/en
\par \hich\af44\dbch\af31505\loch\f44 67. Sangeetha, S. PHARMACOKINETICS: BASIC CONSIDERATIONS Plasma Drug Concentration}{\rtlch\fcs1 \af34\afs24 \ltrch\fcs0 \f34\fs24\cf1\insrsid7741077 \loch\af34\dbch\af31505\hich\f34 \u8208\'2d}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 Time Profile Plotting Da\hich\af44\dbch\af31505\loch\f44 ta. Retrieved from http://www.srmuniv.ac.in/sites/default/files/files/PharmacokineticsBasicConsiderations.pdf
\par \hich\af44\dbch\af31505\loch\f44 68. \~\~Sunshine A, et al. Analgesic Efficacy of Controlled-Release Oxycodone in Postoperative Pain. }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 
J Clin Pharmacol.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  1996;595-603.
\par \hich\af44\dbch\af31505\loch\f44 69. \~\~Stein, SH\hich\af44\dbch\af31505\loch\f44 . Purdue Pharma LP against Endo Pharmaceuticals v. Euroceltique S.A., Opinion and Order. \~
16, 40. 7-5-2004. New York, New York, US District Court: Southern District of New York.
\par \hich\af44\dbch\af31505\loch\f44 70. Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid Dose and \hich\af44\dbch\af31505\loch\f44 Drug-Related Mortality in Patients With Nonmalignant Pain. }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 
\i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 Arch Intern Med.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  2011;171(7):686\hich\f44 \endash \loch\f44 
691. doi:10.1001/archinternmed.2011.117
\par \hich\af44\dbch\af31505\loch\f44 71. \~Long-acting OxyContin 174 tablets now available in 160 mg strength to relieve persistent pain. (2000). Retrieved from h\hich\af44\dbch\af31505\loch\f44 
ttps://www.eurekalert.org/pub_releases/2000-07/PN-LOtn-0907100.php
\par \hich\af44\dbch\af31505\loch\f44 72. Answers to Frequently Asked Questions Regarding OxyContin. Retrieved from https://www.deadiversion.usdoj.gov/drug_chem_info/oxycodone/oxycontin_faq.htm#7
\par }\pard \ltrpar\ql \fi-720\li720\ri0\nowidctlpar\wrapdefault\faauto\rin0\lin720\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 73. FDA (2015). Highlights of O\hich\af44\dbch\af31505\loch\f44 
\hich\f44 xyContin\'ae\loch\f44  Prescribing Information. Retrieved from
\par \hich\af44\dbch\af31505\loch\f44 http://app.purduepharma.com/xmlpublishing/pi.aspx?id=o
\par }\pard \ltrpar\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
74. Birkett, D. (1996). Pharmacokinetics made easy 11 Designing dose regimens. Australian Prescriber, 19(3), 76-78. doi: 10.18773/austprescr.1996.069
\par \hich\af44\dbch\af31505\loch\f44 7\hich\af44\dbch\af31505\loch\f44 5. National Pain Centre. Opioid Tapering Information [Document]. Retrieved from http://nationalpaincentre.mcmaster.ca/documents/Opioid%20Tapering%20Patient%20Information%20(english).pdf

\par \hich\af44\dbch\af31505\loch\f44 76. OxyContin New FDA Drug Approval. Retrieved from https://www.center\hich\af44\dbch\af31505\loch\f44 watch.com/drug-information/fda-approved-drugs/drug/120/oxycontin-oxycodone-hcl-controlled-release
\par \hich\af44\dbch\af31505\loch\f44 77. Harris, Hodges, & Snively. (2002). OxyContin in Missouri: A Policy Brief Exploring Patterns of Abuse [Document]. The Missouri Division of Alcohol and Drug\hich\af44\dbch\af31505\loch\f44 
 Abuse through its grant from the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. Retrieved from https://dmh.mo.gov/docs/ada/oxycontinbrief.pdf
\par \hich\af44\dbch\af31505\loch\f44 78. \~\~Purdue Pharma. Purdue Pharma Product Data Brochure. \~3-27\hich\af44\dbch\af31505\loch\f44 -2000. https://repository.library.brown.edu/studio/item/bdr:841739/
\par \hich\af44\dbch\af31505\loch\f44 79. \~OxyContin / Oxycodone. Retrieved from https://www.ctclearinghouse.org/topics/oxycontin-oxycodone/
\par \hich\af44\dbch\af31505\loch\f44 80. \~\~Welch JS. Letter to the Editor: \~Risk of Intravenous Abuse of Oral Morphine. }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 Am
\hich\af45\dbch\af31505\loch\f45  Fam Physician.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  1997;56:1307-1308.
\par \hich\af44\dbch\af31505\loch\f44 81. \~\~Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. }{\rtlch\fcs1 \ai\af45\afs24 
\ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 Drug Alcohol Depend.}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44  2003;69:215-2\hich\af44\dbch\af31505\loch\f44 32.\tab 
\tab \tab \tab \tab \tab \tab 
\par \hich\af44\dbch\af31505\loch\f44 82. \~\~Purdue Pharma. 24 Hours of Oxycodone Pain Control - The Old Way- The New Way. \~16-17. 1996. https://repository.library.brown.edu/studio/item/bdr:841742/
\par \hich\af44\dbch\af31505\loch\f44 83. Nieminen, T. H., Hagelberg, N. M., Saari, T. I., Neuvonen, M., Neuvonen, P. J., Laine, K., & Olkkola, K. T. (2010). Grapefruit juice enhances the exposure to oral oxycodone. }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 
\i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 Basic and Clinical Pharmacology and Toxicology}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 , }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 
\i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 107}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 (4), 782\hich\f44 \endash \loch\f44 788. https://doi.o\hich\af44\dbch\af31505\loch\f44 
rg/10.1111/j.1742-7843.2010.00582.x
\par \hich\af44\dbch\af31505\loch\f44 84. Malhotra, BK (2015). Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02). 2015 Apr;35(4):267-74. doi: 10.1007/s40261-015-0278-6
\par \hich\af44\dbch\af31505\loch\f44 85. Malhotra, B. K., Mastschke\hich\af44\dbch\af31505\loch\f44 
, K., Wang, Q., Bramson, C., & Salageanu, J. (2015). Effects of Ethanol on the Pharmacokinetics of Extended-Release Oxycodone with Sequestered Naltrexone (ALO-O2). }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 
\hich\af45\dbch\af31505\loch\f45 Clinical Drug Investigation}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 , }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 
\hich\af45\dbch\af31505\loch\f45 35}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 (4), 267\hich\f44 \endash \loch\f44 274.
\par \hich\af44\dbch\af31505\loch\f44 86. Sheckler, C. (2015). Charges filed in conne\hich\af44\dbch\af31505\loch\f44 ction with party where Granger brothers overdosed. }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 
\hich\af45\dbch\af31505\loch\f45 South Bend Tribune}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 
. https://www.southbendtribune.com/news/publicsafety/charges-filed-in-connection-with-party-where-granger-brothers-overdosed/article_dc4abebc-2fba-11e5-a3ec-ff9ce46db843.html
\par \hich\af44\dbch\af31505\loch\f44 87. Sheckler\hich\af44\dbch\af31505\loch\f44 , C. (2015). Coroner confirms cause of death in Granger brother overdoses. }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 
\hich\af45\dbch\af31505\loch\f45 South Bend Tribune}{\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 .
\par \hich\af44\dbch\af31505\loch\f44 88. \~\~Viscusi W, Vernon J, Harrington J. }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 Economics of Regulation and Antitrust}{\rtlch\fcs1 \af44\afs24 
\ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 . Third ed. Cambridge: The MIT Press; 2000.
\par \hich\af44\dbch\af31505\loch\f44 89. Janis IL. }{\rtlch\fcs1 \ai\af45\afs24 \ltrch\fcs0 \i\f45\fs24\cf1\insrsid7741077 \hich\af45\dbch\af31505\loch\f45 Groupthink : psychologica\hich\af45\dbch\af31505\loch\f45 l studies of policy decisions and fiascoes}{
\rtlch\fcs1 \af44\afs24 \ltrch\fcs0 \f44\fs24\cf1\insrsid7741077 \hich\af44\dbch\af31505\loch\f44 . 2nd ed. Boston: Houghton Mifflin, 1983, p.xii, 351 p.
\par \hich\af44\dbch\af31505\loch\f44 90. \~\~Friedman, Milton. "The Social Responsibility of Business is to Increase its Profits". New York Times Magazine . 9-13-1970. New York, New York Times Co.}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid7741077 
\par }{\*\themedata 504b030414000600080000002100e9de0fbfff0000001c020000130000005b436f6e74656e745f54797065735d2e786d6cac91cb4ec3301045f748fc83e52d4a
9cb2400825e982c78ec7a27cc0c8992416c9d8b2a755fbf74cd25442a820166c2cd933f79e3be372bd1f07b5c3989ca74aaff2422b24eb1b475da5df374fd9ad
5689811a183c61a50f98f4babebc2837878049899a52a57be670674cb23d8e90721f90a4d2fa3802cb35762680fd800ecd7551dc18eb899138e3c943d7e503b6
b01d583deee5f99824e290b4ba3f364eac4a430883b3c092d4eca8f946c916422ecab927f52ea42b89a1cd59c254f919b0e85e6535d135a8de20f20b8c12c3b0
0c895fcf6720192de6bf3b9e89ecdbd6596cbcdd8eb28e7c365ecc4ec1ff1460f53fe813d3cc7f5b7f020000ffff0300504b030414000600080000002100a5d6
a7e7c0000000360100000b0000005f72656c732f2e72656c73848fcf6ac3300c87ef85bd83d17d51d2c31825762fa590432fa37d00e1287f68221bdb1bebdb4f
c7060abb0884a4eff7a93dfeae8bf9e194e720169aaa06c3e2433fcb68e1763dbf7f82c985a4a725085b787086a37bdbb55fbc50d1a33ccd311ba548b6309512
0f88d94fbc52ae4264d1c910d24a45db3462247fa791715fd71f989e19e0364cd3f51652d73760ae8fa8c9ffb3c330cc9e4fc17faf2ce545046e37944c69e462
a1a82fe353bd90a865aad41ed0b5b8f9d6fd010000ffff0300504b0304140006000800000021006b799616830000008a0000001c0000007468656d652f746865
6d652f7468656d654d616e616765722e786d6c0ccc4d0ac3201040e17da17790d93763bb284562b2cbaebbf600439c1a41c7a0d29fdbd7e5e38337cedf14d59b
4b0d592c9c070d8a65cd2e88b7f07c2ca71ba8da481cc52c6ce1c715e6e97818c9b48d13df49c873517d23d59085adb5dd20d6b52bd521ef2cdd5eb9246a3d8b
4757e8d3f729e245eb2b260a0238fd010000ffff0300504b030414000600080000002100b6f4679893070000c9200000160000007468656d652f7468656d652f
7468656d65312e786d6cec59cd8b1bc915bf07f23f347d97f5d5ad8fc1f2a24fcfda33b6b164873dd648a5eef2547789aad28cc56208de532e81c026e49085bd
ed21842cecc22eb9e48f31d8249b3f22afaa5bdd5552c99e191c3061463074977eefd5afde7bf5de53d5ddcf5e26d4bbc05c1096f6fcfa9d9aefe174ce16248d
7afeb3d9a4d2f13d2151ba4094a5b8e76fb0f03fbbf7eb5fdd454732c609f6403e1547a8e7c752ae8eaa5531876124eeb0154ee1bb25e30992f0caa3ea82a34b
d09bd06aa3566b55134452df4b51026a1f2f97648ebd9952e9dfdb2a1f53784da5500373caa74a35b6243476715e5708b11143cabd0b447b3eccb3609733fc52
fa1e4542c2173dbfa6fffceabdbb5574940b517940d6909be8bf5c2e17589c37f49c3c3a2b260d823068f50bfd1a40e53e6edc1eb7c6ad429f06a0f91c569a71
b175b61bc320c71aa0ecd1a17bd41e35eb16ded0dfdce3dc0fd5c7c26b50a63fd8c34f2643b0a285d7a00c1feee1c3417730b2f56b50866fede1dbb5fe28685b
fa3528a6243ddf43d7c25673b85d6d0159327aec8477c360d26ee4ca4b144443115d6a8a254be5a1584bd00bc6270050408a24493db959e1259a43140f112567
9c7827248a21f056286502866b8ddaa4d684ffea13e827ed5174849121ad780113b137a4f87862cec94af6fc07a0d537206f7ffef9cdeb1fdfbcfee9cd575fbd
79fdf77c6eadca923b466964cafdf2dd1ffef3cd6fbd7ffff0ed2f5fff319b7a172f4cfcbbbffdeedd3ffef93ef5b0e2d2146ffff4fdbb1fbf7ffbe7dfffebaf
5f3bb4f7393a33e1339260e13dc297de5396c0021dfcf119bf9ec42c46c494e8a791402952b338f48f656ca11f6d10450edc00db767cce21d5b880f7d72f2cc2
d398af2571687c182716f094313a60dc6985876a2ec3ccb3751ab927e76b13f714a10bd7dc43945a5e1eaf579063894be530c616cd2714a5124538c5d253dfb1
738c1dabfb8210cbaea764ce99604be97d41bc01224e93ccc899154da5d03149c02f1b1741f0b7659bd3e7de8051d7aa47f8c246c2de40d4417e86a965c6fb68
2d51e252394309350d7e8264ec2239ddf0b9891b0b099e8e3065de78818570c93ce6b05ec3e90f21cdb8dd7e4a37898de4929cbb749e20c64ce4889d0f6394ac
5cd829496313fbb938871045de13265df05366ef10f50e7e40e941773f27d872f787b3c133c8b026a53240d4376beef0e57dccacf89d6ee8126157aae9f3c44a
b17d4e9cd131584756689f604cd1255a60ec3dfbdcc160c05696cd4bd20f62c82ac7d815580f901dabea3dc5027a25d5dcece7c91322ac909de2881de073bad9
493c1b9426881fd2fc08bc6eda7c0ca52e7105c0633a3f37818f08f480102f4ea33c16a0c308ee835a9fc4c82a60ea5db8e375c32dff5d658fc1be7c61d1b8c2
be04197c6d1948eca6cc7b6d3343d49aa00c9819822ec3956e41c4727f29a28aab165b3be596f6a62ddd00dd91d5f42424fd6007b4d3fb84ffbbde073a8cb77f
f9c6b10f3e4ebfe3566c25ab6b763a8792c9f14e7f7308b7dbd50c195f904fbfa919a175fa04431dd9cf58b73dcd6d4fe3ffdff73487f6f36d2773a8dfb8ed64
7ce8306e3b99fc70e5e3743265f3027d8d3af0c80e7af4b14f72f0d46749289dca0dc527421ffc08f83db398c0a092d3279eb838055cc5f0a8ca1c4c60e1228e
b48cc799fc0d91f134462b381daafb4a492472d591f0564cc0a1911e76ea5678ba4e4ed9223becacd7d5c16656590592e5782d2cc6e1a04a66e856bb3cc02bd4
6bb6913e68dd1250b2d721614c6693683a48b4b783ca48fa58178ce620a157f65158741d2c3a4afdd6557b2c805ae115f8c1edc1cff49e1f06200242701e07cd
f942f92973f5d6bbda991fd3d3878c69450034d8db08283ddd555c0f2e4fad2e0bb52b78da2261849b4d425b46377822869fc17974aad1abd0b8aeafbba54b2d
7aca147a3e08ad9246bbf33e1637f535c8ede6069a9a9982a6de65cf6f35430899395af5fc251c1ac363b282d811ea3717a211dcbccc25cf36fc4d32cb8a0b39
4222ce0cae934e960d122231f728497abe5a7ee1069aea1ca2b9d51b90103e59725d482b9f1a3970baed64bc5ce2b934dd6e8c284b67af90e1b35ce1fc568bdf
1cac24d91adc3d8d1797de195df3a708422c6cd795011744c0dd413db3e682c0655891c8caf8db294c79da356fa3740c65e388ae62945714339967709dca0b3a
faadb081f196af190c6a98242f8467912ab0a651ad6a5a548d8cc3c1aafb6121653923699635d3ca2aaa6abab39835c3b60cecd8f26645de60b53531e434b3c2
67a97b37e576b7b96ea74f28aa0418bcb09fa3ea5ea12018d4cac92c6a8af17e1a56393b1fb56bc776811fa07695226164fdd656ed8edd8a1ae19c0e066f54f9
416e376a6168b9ed2bb5a5f5adb979b1cdce5e40f2184197bba6526857c2c92e47d0104d754f92a50dd8222f65be35e0c95b73d2f3bfac85fd60d80887955a27
1c57826650ab74c27eb3d20fc3667d1cd66ba341e31514161927f530bbb19fc00506dde4f7f67a7cefee3ed9ded1dc99b3a4caf4dd7c5513d777f7f5c6e1bb7b
8f40d2f9b2d598749bdd41abd26df627956034e854bac3d6a0326a0ddba3c9681876ba9357be77a1c141bf390c5ae34ea5551f0e2b41aba6e877ba9576d068f4
8376bf330efaaff23606569ea58fdc16605ecdebde7f010000ffff0300504b0304140006000800000021000dd1909fb60000001b010000270000007468656d65
2f7468656d652f5f72656c732f7468656d654d616e616765722e786d6c2e72656c73848f4d0ac2301484f78277086f6fd3ba109126dd88d0add40384e4350d36
3f2451eced0dae2c082e8761be9969bb979dc9136332de3168aa1a083ae995719ac16db8ec8e4052164e89d93b64b060828e6f37ed1567914b284d262452282e
3198720e274a939cd08a54f980ae38a38f56e422a3a641c8bbd048f7757da0f19b017cc524bd62107bd5001996509affb3fd381a89672f1f165dfe514173d985
0528a2c6cce0239baa4c04ca5bbabac4df000000ffff0300504b01022d0014000600080000002100e9de0fbfff0000001c020000130000000000000000000000
0000000000005b436f6e74656e745f54797065735d2e786d6c504b01022d0014000600080000002100a5d6a7e7c0000000360100000b00000000000000000000
000000300100005f72656c732f2e72656c73504b01022d00140006000800000021006b799616830000008a0000001c0000000000000000000000000019020000
7468656d652f7468656d652f7468656d654d616e616765722e786d6c504b01022d0014000600080000002100b6f4679893070000c92000001600000000000000
000000000000d60200007468656d652f7468656d652f7468656d65312e786d6c504b01022d00140006000800000021000dd1909fb60000001b01000027000000
000000000000000000009d0a00007468656d652f7468656d652f5f72656c732f7468656d654d616e616765722e786d6c2e72656c73504b050600000000050005005d010000980b00000000}
{\*\colorschememapping 3c3f786d6c2076657273696f6e3d22312e302220656e636f64696e673d225554462d3822207374616e64616c6f6e653d22796573223f3e0d0a3c613a636c724d
617020786d6c6e733a613d22687474703a2f2f736368656d61732e6f70656e786d6c666f726d6174732e6f72672f64726177696e676d6c2f323030362f6d6169
6e22206267313d226c743122207478313d22646b3122206267323d226c743222207478323d22646b322220616363656e74313d22616363656e74312220616363
656e74323d22616363656e74322220616363656e74333d22616363656e74332220616363656e74343d22616363656e74342220616363656e74353d22616363656e74352220616363656e74363d22616363656e74362220686c696e6b3d22686c696e6b2220666f6c486c696e6b3d22666f6c486c696e6b222f3e}
{\*\latentstyles\lsdstimax375\lsdlockeddef0\lsdsemihiddendef0\lsdunhideuseddef0\lsdqformatdef0\lsdprioritydef99{\lsdlockedexcept \lsdqformat1 \lsdpriority0 \lsdlocked0 Normal;\lsdqformat1 \lsdpriority9 \lsdlocked0 heading 1;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 2;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 3;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 4;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 5;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 6;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 7;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 8;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 9;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 index 1;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 index 2;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 index 3;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 index 4;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 index 5;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 index 6;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 index 7;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 index 8;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 index 9;
\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 1;\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 2;\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 3;
\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 4;\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 5;\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 6;
\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 7;\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 8;\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 9;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Normal Indent;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 footnote text;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 annotation text;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 header;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 footer;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 index heading;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority35 \lsdlocked0 caption;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 table of figures;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 envelope address;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 envelope return;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 footnote reference;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 annotation reference;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 line number;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 page number;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 endnote reference;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 endnote text;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 table of authorities;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 macro;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 toa heading;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List Bullet;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List Number;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List 2;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List 3;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List 4;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List 5;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List Bullet 2;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List Bullet 3;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List Bullet 4;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List Bullet 5;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List Number 2;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List Number 3;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List Number 4;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List Number 5;\lsdqformat1 \lsdpriority10 \lsdlocked0 Title;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Closing;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Signature;\lsdsemihidden1 \lsdunhideused1 \lsdpriority1 \lsdlocked0 Default Paragraph Font;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Body Text;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Body Text Indent;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List Continue;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List Continue 2;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List Continue 3;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List Continue 4;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List Continue 5;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Message Header;\lsdqformat1 \lsdpriority11 \lsdlocked0 Subtitle;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Salutation;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Date;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Body Text First Indent;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Body Text First Indent 2;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Note Heading;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Body Text 2;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Body Text 3;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Body Text Indent 2;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Body Text Indent 3;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Block Text;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Hyperlink;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 FollowedHyperlink;\lsdqformat1 \lsdpriority22 \lsdlocked0 Strong;
\lsdqformat1 \lsdpriority20 \lsdlocked0 Emphasis;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Document Map;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Plain Text;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 E-mail Signature;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 HTML Top of Form;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 HTML Bottom of Form;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Normal (Web);\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 HTML Acronym;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 HTML Address;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 HTML Cite;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 HTML Code;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 HTML Definition;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 HTML Keyboard;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 HTML Preformatted;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 HTML Sample;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 HTML Typewriter;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 HTML Variable;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Normal Table;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 annotation subject;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 No List;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Outline List 1;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Outline List 2;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Outline List 3;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Simple 1;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Simple 2;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Simple 3;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Classic 1;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Classic 2;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Classic 3;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Classic 4;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Colorful 1;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Colorful 2;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Colorful 3;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Columns 1;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Columns 2;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Columns 3;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Columns 4;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Columns 5;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Grid 1;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Grid 2;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Grid 3;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Grid 4;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Grid 5;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Grid 6;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Grid 7;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Grid 8;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table List 1;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table List 2;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table List 3;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table List 4;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table List 5;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table List 6;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table List 7;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table List 8;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table 3D effects 1;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table 3D effects 2;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table 3D effects 3;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Contemporary;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Elegant;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Professional;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Subtle 1;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Subtle 2;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Web 1;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Web 2;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Web 3;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Balloon Text;\lsdpriority39 \lsdlocked0 Table Grid;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Theme;\lsdsemihidden1 \lsdlocked0 Placeholder Text;
\lsdqformat1 \lsdpriority1 \lsdlocked0 No Spacing;\lsdpriority60 \lsdlocked0 Light Shading;\lsdpriority61 \lsdlocked0 Light List;\lsdpriority62 \lsdlocked0 Light Grid;\lsdpriority63 \lsdlocked0 Medium Shading 1;\lsdpriority64 \lsdlocked0 Medium Shading 2;
\lsdpriority65 \lsdlocked0 Medium List 1;\lsdpriority66 \lsdlocked0 Medium List 2;\lsdpriority67 \lsdlocked0 Medium Grid 1;\lsdpriority68 \lsdlocked0 Medium Grid 2;\lsdpriority69 \lsdlocked0 Medium Grid 3;\lsdpriority70 \lsdlocked0 Dark List;
\lsdpriority71 \lsdlocked0 Colorful Shading;\lsdpriority72 \lsdlocked0 Colorful List;\lsdpriority73 \lsdlocked0 Colorful Grid;\lsdpriority60 \lsdlocked0 Light Shading Accent 1;\lsdpriority61 \lsdlocked0 Light List Accent 1;
\lsdpriority62 \lsdlocked0 Light Grid Accent 1;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 1;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 1;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 1;\lsdsemihidden1 \lsdlocked0 Revision;
\lsdqformat1 \lsdpriority34 \lsdlocked0 List Paragraph;\lsdqformat1 \lsdpriority29 \lsdlocked0 Quote;\lsdqformat1 \lsdpriority30 \lsdlocked0 Intense Quote;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 1;\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 1;
\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 1;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 1;\lsdpriority70 \lsdlocked0 Dark List Accent 1;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 1;\lsdpriority72 \lsdlocked0 Colorful List Accent 1;
\lsdpriority73 \lsdlocked0 Colorful Grid Accent 1;\lsdpriority60 \lsdlocked0 Light Shading Accent 2;\lsdpriority61 \lsdlocked0 Light List Accent 2;\lsdpriority62 \lsdlocked0 Light Grid Accent 2;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 2;
\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 2;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 2;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 2;\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 2;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 2;
\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 2;\lsdpriority70 \lsdlocked0 Dark List Accent 2;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 2;\lsdpriority72 \lsdlocked0 Colorful List Accent 2;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 2;
\lsdpriority60 \lsdlocked0 Light Shading Accent 3;\lsdpriority61 \lsdlocked0 Light List Accent 3;\lsdpriority62 \lsdlocked0 Light Grid Accent 3;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 3;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 3;
\lsdpriority65 \lsdlocked0 Medium List 1 Accent 3;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 3;\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 3;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 3;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 3;
\lsdpriority70 \lsdlocked0 Dark List Accent 3;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 3;\lsdpriority72 \lsdlocked0 Colorful List Accent 3;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 3;\lsdpriority60 \lsdlocked0 Light Shading Accent 4;
\lsdpriority61 \lsdlocked0 Light List Accent 4;\lsdpriority62 \lsdlocked0 Light Grid Accent 4;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 4;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 4;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 4;
\lsdpriority66 \lsdlocked0 Medium List 2 Accent 4;\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 4;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 4;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 4;\lsdpriority70 \lsdlocked0 Dark List Accent 4;
\lsdpriority71 \lsdlocked0 Colorful Shading Accent 4;\lsdpriority72 \lsdlocked0 Colorful List Accent 4;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 4;\lsdpriority60 \lsdlocked0 Light Shading Accent 5;\lsdpriority61 \lsdlocked0 Light List Accent 5;
\lsdpriority62 \lsdlocked0 Light Grid Accent 5;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 5;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 5;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 5;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 5;
\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 5;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 5;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 5;\lsdpriority70 \lsdlocked0 Dark List Accent 5;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 5;
\lsdpriority72 \lsdlocked0 Colorful List Accent 5;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 5;\lsdpriority60 \lsdlocked0 Light Shading Accent 6;\lsdpriority61 \lsdlocked0 Light List Accent 6;\lsdpriority62 \lsdlocked0 Light Grid Accent 6;
\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 6;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 6;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 6;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 6;
\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 6;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 6;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 6;\lsdpriority70 \lsdlocked0 Dark List Accent 6;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 6;
\lsdpriority72 \lsdlocked0 Colorful List Accent 6;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 6;\lsdqformat1 \lsdpriority19 \lsdlocked0 Subtle Emphasis;\lsdqformat1 \lsdpriority21 \lsdlocked0 Intense Emphasis;
\lsdqformat1 \lsdpriority31 \lsdlocked0 Subtle Reference;\lsdqformat1 \lsdpriority32 \lsdlocked0 Intense Reference;\lsdqformat1 \lsdpriority33 \lsdlocked0 Book Title;\lsdsemihidden1 \lsdunhideused1 \lsdpriority37 \lsdlocked0 Bibliography;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority39 \lsdlocked0 TOC Heading;\lsdpriority41 \lsdlocked0 Plain Table 1;\lsdpriority42 \lsdlocked0 Plain Table 2;\lsdpriority43 \lsdlocked0 Plain Table 3;\lsdpriority44 \lsdlocked0 Plain Table 4;
\lsdpriority45 \lsdlocked0 Plain Table 5;\lsdpriority40 \lsdlocked0 Grid Table Light;\lsdpriority46 \lsdlocked0 Grid Table 1 Light;\lsdpriority47 \lsdlocked0 Grid Table 2;\lsdpriority48 \lsdlocked0 Grid Table 3;\lsdpriority49 \lsdlocked0 Grid Table 4;
\lsdpriority50 \lsdlocked0 Grid Table 5 Dark;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 1;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 1;
\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 1;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 1;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 1;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 1;
\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 1;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 2;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 2;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 2;
\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 2;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 2;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 2;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 2;
\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 3;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 3;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 3;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 3;
\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 3;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 3;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 3;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 4;
\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 4;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 4;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 4;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 4;
\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 4;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 4;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 5;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 5;
\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 5;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 5;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 5;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 5;
\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 5;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 6;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 6;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 6;
\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 6;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 6;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 6;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 6;
\lsdpriority46 \lsdlocked0 List Table 1 Light;\lsdpriority47 \lsdlocked0 List Table 2;\lsdpriority48 \lsdlocked0 List Table 3;\lsdpriority49 \lsdlocked0 List Table 4;\lsdpriority50 \lsdlocked0 List Table 5 Dark;
\lsdpriority51 \lsdlocked0 List Table 6 Colorful;\lsdpriority52 \lsdlocked0 List Table 7 Colorful;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 1;\lsdpriority47 \lsdlocked0 List Table 2 Accent 1;\lsdpriority48 \lsdlocked0 List Table 3 Accent 1;
\lsdpriority49 \lsdlocked0 List Table 4 Accent 1;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 1;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 1;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 1;
\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 2;\lsdpriority47 \lsdlocked0 List Table 2 Accent 2;\lsdpriority48 \lsdlocked0 List Table 3 Accent 2;\lsdpriority49 \lsdlocked0 List Table 4 Accent 2;
\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 2;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 2;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 2;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 3;
\lsdpriority47 \lsdlocked0 List Table 2 Accent 3;\lsdpriority48 \lsdlocked0 List Table 3 Accent 3;\lsdpriority49 \lsdlocked0 List Table 4 Accent 3;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 3;
\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 3;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 3;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 4;\lsdpriority47 \lsdlocked0 List Table 2 Accent 4;
\lsdpriority48 \lsdlocked0 List Table 3 Accent 4;\lsdpriority49 \lsdlocked0 List Table 4 Accent 4;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 4;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 4;
\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 4;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 5;\lsdpriority47 \lsdlocked0 List Table 2 Accent 5;\lsdpriority48 \lsdlocked0 List Table 3 Accent 5;
\lsdpriority49 \lsdlocked0 List Table 4 Accent 5;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 5;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 5;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 5;
\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 6;\lsdpriority47 \lsdlocked0 List Table 2 Accent 6;\lsdpriority48 \lsdlocked0 List Table 3 Accent 6;\lsdpriority49 \lsdlocked0 List Table 4 Accent 6;
\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 6;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 6;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 6;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Mention;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Smart Hyperlink;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Hashtag;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Unresolved Mention;}}{\*\datastore 010500000200000018000000
4d73786d6c322e534158584d4c5265616465722e362e3000000000000000000000060000
d0cf11e0a1b11ae1000000000000000000000000000000003e000300feff090006000000000000000000000001000000010000000000000000100000feffffff00000000feffffff0000000000000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
fffffffffffffffffdfffffffeffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffff52006f006f007400200045006e00740072007900000000000000000000000000000000000000000000000000000000000000000000000000000000000000000016000500ffffffffffffffffffffffff0c6ad98892f1d411a65f0040963251e500000000000000000000000000fc
b92dadd9d401feffffff00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000ffffffffffffffffffffffff00000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000ffffffffffffffffffffffff0000000000000000000000000000000000000000000000000000
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000ffffffffffffffffffffffff000000000000000000000000000000000000000000000000
0000000000000000000000000000000000000000000000000105000000000000}}